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        Epidermal growth factor receptor (EGFR) is overexpressed in the majority of head 
and neck cancers. The anti-EGFR antibody cetuximab has been approved by the FDA 
for the treatment of head and neck cancers, however, only a small fraction of patients 
respond to cetuximab treatment. Further investigation to understand the mechanisms 
underlying cetuximab-mediated EGFR-targeted therapy and to develop novel therapeutic 
strategies to improve the efficacy of cetuximab is urgently needed. In the present study, 
we elucidated the mechanism of cetuximab in radiosensitization, and discovered novel 
functions of cetuximab in glycolysis inhibition and cellular redox status regulation. We 
found that cetuximab inhibits radiation-induced hypoxia inducible factor 1 (HIF-1), 
which is required for the radiosensitization role of cetuximab. We also found that 
cetuximab inhibits glycolysis in cancer cells through downregulation of HIF-1, which 
explains the cytostatic effect of cetuximab in the perspective of cancer metabolism. In 
addition, we discovered a novel function of cetuximab in decreasing the anti-oxidant 
capacity of cancer cells through downregulating glutamine transporter ASCT2, which is 
in an EGFR-kinase activity inhibition independent manner. Applications of these 
mechanism studies lead to findings of novel therapeutic targets to improve cetuximab 
vii 
 
responses and/or overcome cetuximab resistance. We proved that targeting HIF-1 
improves response of cetuximab-resistant cancer cells to the combination treatment of 
cetuximab and radiation, while targeting lactate dehydrogenase A (LDH-A) restores the 
role of cetuximab in cell cycle arrest in cetuximab-resistant cancer cells. Moreover, 
targeting pyruvate dehydrogenase kinase 1 (PDK1), in combination with cetuximab, 
leads to a synergetic and synthetic lethality in cancer cells, which bypasses most 
currently known cetuximab resistant mechanisms. In summary, our findings provide 
novel mechanistic insights into cetuximab-mediated EGFR targeted therapy and suggest 
novel therapeutic strategies for enhancing the response of cancer patients to cetuximab 
treatment. 
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Chapter 1 Introduction 
 
1.1 Head and neck squamous cell carcinoma (HNSCC) 
        Head and neck cancer is a biologically similar group of epithelial cancers. Primary 
tumors can occur in the lip, oral cavity, nasal cavity, paranasal sinuses, pharynx, and 
larynx. Head and neck cancer is the sixth leading type of cancer by incident with about 
600,000 new cases each year worldwide [1]. The majority of head and neck cancers are 
squamous cell carcinoma. The five-year survival rate for patients with HNSCC is 
approximately 40-50% [2]. The most important risk factors for head and neck cancers 
are alcohol consumption and tobacco use, which have a synergetic effect [3, 4]. Human 
papillomavirus (HPV) infection is also considered to be a risk factor [5].  
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1.2 Conventional therapy and targeted therapy in HNSCC 
        Conventional treatments for HNSCC include surgery, radiotherapy, chemotherapy, 
and in combination chemo-radiotherapy [6, 7]. For patients at stage I/II when they are 
diagnosed, they are treated with either surgery or radiotherapy [8]. Patients with 
recurrent or metastatic HNSCC will be treated with chemotherapy plus radiotherapy as 
the standard of care [9, 10]. 
        Current conventional therapies are often nonselective and are associated with 
systemic toxicities that often reduce compliance and prevent timely completion of 
therapy. Targeted therapies in HNSCC may minimize toxicity rates and improve 
survival. Potential targeted therapies in HNSCC mainly target cellular pathways of 
carcinogenesis [11, 12]. The signaling pathways deregulated in HNSCC and certain key 
components are being targeted with biological agents (Table 1).  
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Targeting Agent Drug Clinical development phase 
EGFR MAbs Cetuximab, Panitumumab Approved, Phase III 
EGFR tyrosine kinase 
inhibitors 
Gefitinib, Erlotinib Phase III 
VEGFR inhibitors Bevacizumab, Vandetanib Phase III, Phase II 
Multiple kinase inhibitors Sorafenib, Sunitinib, 
Lapatinib 
Phase II 
Src kinase inhibitor Dasatinib Phase II 
mTOR inhibitors Everolimus, Temsirolimus Phase II 
COX inhibitor Celecoxib Phase I 
CDK inhibitors Seliciclib, Flavopiridol Phase I 
Heat shock protein inhibitor Tanespimycin Phase I 
Proteasome inhibitor Bortezomib Phase II 
Histone acetylation 
inhibitors 
Vorinostat, Romidepsin Phase II 
 
Table 1. Targeted biological drugs under development.   
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1.3 Epidermal growth factor receptor (EGFR) 
        The epidermal growth factor receptor (EGFR) is a 170-kd transmembrane 
glycoprotein and belongs to human EGF receptor (HER) family [13]. It is composed of 
an extracellular domain that provides ligand-binding sites, a single transmembrane 
domain and a cytosolic region that contains a juxtamembrane domain, a tyrosine kinase 
domain and a C-terminal tail segment. EGFR is activated by binding with its specific 
ligands, including epidermal growth factor (EGF) and transforming growth factor α 
(TGFα) [14]. Binding with ligands causes the structural changes of EGFR extracellular 
domain and leads to dimerization of two receptor monomers. Receptor dimerization 
leads to activation of intrinsic tyrosine kinase domains and subsequent 
autophosphorylations on multiple tyrosine (Y) residues of the C-terminal tail segments, 
including Y992, Y1045, Y1068, Y1086, Y1148 and Y1173 [15]. These tyrosine 
autophosphorylations create docking motifs for different cytosolic signaling molecules 
containing SH2 (Src homology 2) and PTB (phosphotyrosine binding) domains. 
Through recruiting these molecules, EGFR initiates several downstream signaling 
cascades including the RAS-RAF-MEK-ERK pathway, the PI3K-AKT pathway, the 
PLCγ-PKC pathway, and the STATs pathway (Figure 1) [16]. Activation of these cell 
signalings finally modulates cell proliferation, migration, adhesion, invasion, cell cycle 
progression and differentiation. 
        More than 90% of HNSCCs express a high level of EGFR on the cell surface [17, 
18]. Overexpression of EGFR has been correlated with more aggressive phenotype, 
increased resistance to standard chemotherapy and radiation, and poorer clinical 
outcome [19-25]. EGFR signaling network has emerged as a key target in HNSCC.  
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Figure 1. Downstream signaling cascade of EGFR. 
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1.4 Cetuximab 
        Cetuximab (Erbitux®) is a human-murine chimeric monoclonal antibody directly 
against human EGFR [26]. Cetuximab binds with EGFR competitively with EGF and 
TGF-α, and its affinity for the receptor is 5- to 10-fold higher than that of endogenous 
ligands [26, 27]. Binding of cetuximab to EGFR inhibits ligand-induced dimerization 
and activation of the receptor [28]. Furthermore, it stimulates internalization and 
degradation of the receptor [29], resulting in a decreased responsiveness of EGFR-
bearing cells to endogenous ligands. Cetuximab-induced blockade of receptor-dependent 
signal transduction pathways leads to a number of antitumor effects that have been 
demonstrated in preclinical studies, including inhibition of cell growth and survival, and 
inhibition of angiogenesis and metastasis [30-35]. 
        In randomized, open-label, multinational, phase III clinical trials, cetuximab plus 
radiotherapy significantly improved the duration of locoregional control (primary 
endpoint) compared with radiotherapy alone in patients with locally advanced HNSCC 
(Bonner trial) [23], while cetuximab plus first-line platinum-based chemotherapy 
significantly improved overall survival (primary endpoint) compared with first-line 
platinum-based chemotherapy alone in patients with recurrent and/or metastatic HNSCC 
(EXTREME trial) [36]. Based on the results above, cetuximab was approved by the 
FDA in March 2006 for use in combination with radiation therapy for treating HNSCC 
or as a single agent in HNSCC patients who have had prior platinum-based therapy. 
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1.5 Hypoxia inducible factors (HIFs) 
        It has been estimated that 50–60% of solid tumors contain hypoxic tissues that 
develop as a result of an imbalance between limited oxygen supply and fast consumption 
in proliferating tumors [37]. Tumor hypoxia has been known to contribute to tumor 
radioresistance and poor clinical outcomes of human cancers for over half century [38, 
39]. Hypoxia inducible factors (HIFs) are essential mediators of the cellular oxygen-
signaling pathway [40]. HIFs are the members of the PAS (PER-ARNT-SIM) family of 
basic helix-loop-helix (bHLH) transcription factors. To date, three HIFs (HIF-1, -2, and -
3) have been identified that regulate transcriptional programs in response to hypoxia 
(Figure 2).  
        The active HIF transcription factors are heterodimers composed of an oxygen- 
sensitive α subunit and a constitutively expressed β subunit, also known as ARNT. All α 
subunit of HIFs have bHLH, PAS, and ODD (oxygen degradation dependent) domain, 
and share 50-60% homology with each other. ARNT is the general binding partner for 
all three α subunits of HIFs [41, 42]. ARNT does not have an ODD domain, and is 
therefore constitutively expressed in all tissues under aerobic conditions. 
        Under normoxic condition, HIFs are degradation by the von Hippel–Lindau (VHL) 
tumor suppressor, pVHL, the substrate recognition component of an E3 ubiquitin ligase 
complex that interacts with HIF-α in an oxygen-dependent manner [43]. Prolyl-4-
hydroxylase domain (PHD)-containing proteins hydroxylate conserved proline residues 
within the HIF-α-ODD domain and mediate pVHL binding and degradation of HIF-α 
[44, 45]. Under hypoxic condition, HIF-α subunits are stabilized and translocate to the 
nucleus, where they form heterodimer with β subunit and bind to hypoxia response 
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elements (HREs) of HIF target genes (Figure 3). Once stabilized, the HIF heterodimer 
activates transcription by recruiting the transcriptional activators p300 and CBP. The 
interaction between HIF and p300/CBP is also regulated in an oxygen-dependent manner 
by factor inhibiting HIF-1 (FIH-1) [46]. FIH hydroxylates asparagine residues located 
within the HIF-α C-terminal transactivation domain (CTAD) and prevents p300/CBP 
binding [47].  
        The activities of HIFs can also be regulated through its protein synthesis pathway in 
an oxygen-independent manner. Growth factors binding to tyrosine kinase receptor will 
activate PI3K-Akt-mTOR pathway and MAPK pathway [48-50]. Activation of these two 
pathways will cause the activation of p70 S6 kinase (S6K), and inactivation of the 
eukaryotic translation initiation factor 4E (eIF-4E) binding protein (4E-BP1), and lead to 
the increase of translation rate of a subset of mRNA to protein, including HIFs.  
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Figure 2. Schematic representation of HIF family member protein domains. 
 
 
 
                
                  
 
 
 
 
 
  
Figure 3. Activation of HIFs by hypoxia.  
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1.6 HIF-1 function in cancer 
        HIF-1 was the first HIF family members to be cloned and is the best understood 
isoform [51]. It is considered to be the master regulator of cellular responses to hypoxia 
[52]. As described in 1.5, HIF-1 is a heterodimer that consists of a constitutively 
expressed HIF-1β subunit and a HIF-1α subunit, the expression of which is highly 
regulated. As a transcription factor, HIF-1 directly regulates more than 100 genes that 
are related with tumorigenesis, including key steps in glucose metabolism, angiogenesis, 
erythropoiesis, proliferation, metastasis, and apoptosis. Table 2 lists some of direct 
downstream targets of HIF-1.  
 
Metabolism Angiogenesis Erythropoiesis Proliferation Metastasis 
GLUT1/3 VEGF EPO Cyclin G2 KRT14/18/19 
HK1/2 VEGFR CP IGF-BP VIM 
ENO1 ENG TF TGF-α MIC2 
GAPDH HO1 TFR WAF1 CATHD 
PFKBF3 NOS2  ADM FN1 
PFKL PAI1  NIP3 MMP2 
PGK1   MDR c-MET 
PKM    LRP1 
TP1     
ALDA     
LEP     
LDHA     
 
Table 2. HIF-1 target genes and their roles in cancer.  
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1.7 Warburg effect 
        As early as 1920s, Otto Warburg observed that tumor cells rapidly use glucose and 
convert the majority of it to lactate [53, 54]. After revision and expansion by tumor 
biologists in the past century, it is widely accepted that cancer cells adopt a new form of 
metabolism. In contrast with normal cells, cancer cells prefer to convert glucose to 
lactate, even in the presence of abundant oxygen. This phenomenon, an emerging 
hallmark of cancer and fast proliferating cells, is so called aerobic glycolysis, or 
Warburg effect (Figure 4).  Because of low efficiency of glycolysis in generating ATP, 
the reliance of tumor cells on glycolysis for energy production causes them to consume 
more glucose [55].  
 
 
Figure 4. Schematic representation of Warburg effect.  
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1.8 Regulation of Warburg effect by HIF-1 
        Although the reasons for altered cancer metabolism are complex and are not fully 
understood, activation of HIF-1 in cancer cells is considered to be one of the principal 
molecular mechanisms underlying Warburg effect. Activation of HIF-1 and HIF-1 
transcriptional program has two major effects on metabolism in cancer cells (Figure 5). 
First, HIF-1 promotes glycolysis through activating genes involved in glucose uptake, 
enzymes for glycolysis, conversion of pyruvate to lactate, and lactate export [56-63]. 
Second, HIF-1 inhibits mitochondrial function and decrease the rate of oxidative 
phosphorylation [64-67]. Activation of HIF-1 switched glucose metabolism from 
oxidative phosphorylation towards aerobic glycolysis.  
        As the rate of glycolysis increases in cancer cells, more pyruvate, the product of 
glycolysis, is produced. Two critical HIF-1 targets that contribute to HIF-1-regulated 
metabolic changes in cancer are lactate dehydrogenase A (LDH-A) and pyruvate 
dehydrogenase kinase 1 (PDK1), both of which are directly related with pyruvate 
conversion. LDH-A is induced by HIF-1 and this enzyme converts pyruvate to lactate. 
Activation of LDH-A by HIF-1 will increase the conversion of pyruvate to lactate. 
PDK1 phosphorylates and negatively regulates the E1 subunit of the mitochondrial 
enzyme pyruvate dehydrogenase (PDH), which catalyses the broken down of pyruvate to 
acetyl-CoA and CO2.  Through activating PDK1 and inactivating PDH, HIF-1 blocks the 
flow of pyruvate into mitochondria and leads to a reduction in oxidative phosphorylation.  
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Figure 5. HIF-1 mediated regulation of cancer cell metabolism.  
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1.9 Reactive oxygen species (ROS) and cellular redox homeostasis 
        One of the major advantages cancer cells prefer aerobic glycolysis to oxidative 
phosphorylation as the energy source is to avoid overproduction of reactive oxygen 
species [68]. Cellular ROS are generated endogenously as in the process of 
mitochondrial oxidative phosphorylation, through which molecular oxygen (O2) is 
reduced to form superoxide anion (O2 −), and then converted to hydrogen peroxide 
(H2O2) through the action of superoxide dismutases (SODs) [69]. ROS is majorly 
produced in Complex I, II, and III of electron transport chain (ETC), where electrons can 
prematurely reduce oxygen [70].  
        The level of intracellular ROS is tightly controlled, or the term redox homeostasis is 
used. Low levels of mitochondrial ROS production are required for proliferation and 
differentiation. An induction in ROS production will lead to adaptive programs 
including the transcriptional upregulation of antioxidant genes. Overproduction of ROS 
will lead to the initiation of senescence and apoptosis. The highest levels of cellular ROS 
will cause non-signaling, irreversible damage to cellular components (Figure 6) 
        Since cancer cells have elevated ROS generation and are under increased intrinsic 
oxidative stress, they are more dependent on antioxidants for cell survival and more 
vulnerable to further oxidative insults induced by agents that generate ROS or decrease 
the cellular antioxidant capacity.  It is a convincing therapeutic approach to induce 
preferential cancer cell death by a ROS-mediated mechanism based on the different 
redox states in normal and malignant cells.  
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.  
Figure 6. Mitochondrial ROS levels dictate biological outcomes.  
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1.10 Glutathione and its synthesis 
        Glutathione (γ-glutamyl-cysteinyl-glycine) is a tripeptide enzymatically formed by 
glycine, cysteine, and glutamate, and is the most abundant non-protein thiol in 
mammalian cells [71]. The reduced form of glutathione GSH and the oxidative form of 
glutathione GSSG is the major couple to maintain intracellular redox homeostasis. GSH 
acts as a reducing agent and is the major ROS-scavenging system in cells. The important 
redox-modulating enzymes, including the peroxidases, peroxiredoxins and thiol 
reductases, rely on GSH as their source of reducing equivalents [72]. 
        The synthesis of glutathione from glutamate, cysteine, and glycine is catalyzed 
sequentially by two cytosolic enzymes, γ-glutamylcysteine synthetase (GCS) and GSH 
synthetase [73]. Traditionally, the availability of cysteine and the activity of GCS were 
considered as the rate-limit step for the synthesis of glutathione [74]. Recent data 
showed that glycine deprivation also significantly decrease the intracellular GSH level 
[75]. In addition, the formation of GSH is also relied on glutamine, because glutamine 
metabolism produces glutamate and glutamate pool is necessary for cells to acquire 
cysteine [76]. 
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1.11 Glutamine metabolism  
        Glutamine is the most abundant amino acid in the plasma. In cell culture, tumor 
cells metabolize glutamine at rates far in excess of any other amino acid [77]. Glutamine 
supports cell survival, growth and proliferation through metabolic and non-metabolic 
mechanisms [76]. After its import through surface transporters, glutamine is either 
exported in exchange with the import of essential amino acids (EAAs) or converted to 
glutamate catalyzed by the mitochondrial enzyme glutaminase. The γ-nitrogen of 
glutamine provides nitrogen for nucleotide and hexosamine biosynthesis. Glutamate can 
be converted to some other non-essential amino acid (NEAA), or metabolized as a 
respiratory substrate through glutaminolysis, or work as a precursor for the synthesis of 
GSH.  
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Chapter 2 Materials and Methods 
 
2.1 Cell lines and cell culture 
        HNSCC cell lines HN5, FaDu, UMSCC1, OSC19, TU167, and Sqcc/Y1, UMSCC2, 
UMSCC22A, UMSCC22B, MDA1986, and HN30 were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM)/F12 medium supplemented with 10% fetal bovine 
serum, 2 mM glutamine, 100 units/mL penicillin, and 100 µg/mL streptomycin under 
conditions of 5% CO2 at 37 °C in an incubator. Cetuximab acquired resistant HN5-R 
and FaDu-R cells were generated by exposing parental HN5 and FaDu cells to 
cetuximab containing media for more than 1 year with stepwise increases in 
concentration up to 20 nM. HN5-HIF-1α-∆ODD and FaDu-HIF-1α-∆ODD cells were 
established by transfecting parental HN5 and FaDu cells with pcDNA3.1 construct 
containing a HIF-1α oxygen-dependent degradation domain deletion mutant (referred to 
as HIF-1α-∆ODD) using Lipofectamine 2000 (Life Technologies, Carlsbad, CA) and 
maintained in medium containing 500 µg/mL neomycin. Immortalized nontransformed 
NOM9-TK human head and neck epithelial cells were maintained in serum-free 
keratinocyte basal growth medium supplemented with components in KGM SingleQuots 
kit including bovine pituitary extract, recombinant human EGF, insulin, hydrocortisone, 
and gentamicin sulfate (Lonza, Inc.,Walkersville, MD).  
2.2 Reagents 
        Cetuximab was provided by ImClone System, an Eli Lilly company (New York, 
NY), 1-methyl-1, 9 pyrazoloanthrone (1-methyl 1, 9 PA) was purchased from 
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CalBiochem/EMD Chemicals, Inc. (Gibbstown, NJ), oxamate and dicholoroacetate were 
purchased from Sigma-Aldrich (St. Louis, MO).  
2.3 Western blot analysis 
        Cultured cells were lysed in a lysis buffer containing 50 mM TrisHCl (pH 7.4), 150 
mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl 
fluoride, 25 µg/ml aprotinin, and 25 µg/ml leupeptin and kept on ice for 15 min. The 
lysates were cleared by centrifugation, and the supernatants were collected. Equal 
amounts of protein lysate, as determined using the Pierce Coomassie Plus colorimetric 
protein assay (Thermo Fisher Scientific), were separated by SDS–PAGE, blotted onto 
nitrocellulose, and probed with the intended primary antibodies (Table 3). The signals 
were visualized using the enhanced chemiluminescence detection kit (Amersham 
Biosciences, Piscataway, NJ). 
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Table 3. List of antibodies.  
  
Primary Antibody Vendor
EGFR-Y1068p Cell Signaling Technology
EGFR Sigma-Aldrich
Akt-S473p Cell Signaling Technology
Akt Cell Signaling Technology
Erk-T202/Y204p Cell Signaling Technology
Erk Santa Cruz Biotechnology
Ras Cell Signaling Technology
HIF-1α BD Transduction Laboratories
LDH-A Cell Signaling Technology
PDK1 Enzo Life Sciences
PDH-S293p Novus Biologicals
PDH Cell Signaling Technology
PARP Cell Signaling Technology
cleaved Caspase-3 Cell Signaling Technology
Caspase-3 Cell Signaling Technology
Rab5 Abcam
Rab11 Abcam
ASCT2 Santa Cruz Biotechnology
xCT Santa Cruz Biotechnology
β-actin Sigma-Aldrich
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2.4 cDNA construct, siRNA and transfection 
        The pcDNA3.1 expression constructs containing HIF-1α-∆ODD were kindly 
provided by Dr. L. Eric Huang (University of Utah), and the pcDNA3.1 expression 
constructs containing pBI-GL-V6L were kindly provided by Dr. Van Meir EG (Emory 
University). The RasG12V and ASCT2 cDNAs were subcloned to pcDNA3.1 
expression vector (Invitrogen, Carlsbad, CA). The siRNA oligonucleotide duplexes 
targeting HIF-1α, LDHA, PDK1, ASCT2, EGFR, Rab5 and Rab11 are listed in Table 4. 
The cDNA constructs and the siRNA oligonucleotides were transfected into the targeted 
cells with Lipofectamine 2000 according to the manufacturer’s instructions.  
 
Target Gene Target DNA Sequence Vender
HIF-1α (in Chapter 3) AACTGATGACCAGCAACTTGA Qiagen
HIF-1α (in Chapter 4) #1: CAAAGTTCACCTGAGCCTA Sigma-Aldrich
#2: GATTAACTCAGTTTGAACT Sigma-Aldrich
LDH-A #1: GGAGAAAGCCGTCTTAATT Sigma-Aldrich
#2: GATTAAGGGTCTTTACGGA Sigma-Aldrich
#3: CAGATTTAGGGACTGATAA Sigma-Aldrich
PDK1 #1: GGATGAAATTGCACCTATT Sigma-Aldrich
#2: GTCCAGGAGACTGTGTCAT Sigma-Aldrich
#3: TGCTAGGCGTCTGTGTGAT Sigma-Aldrich
ASCT2 #1: GTCAGCAGCCTTTCGCTCA Sigma-Aldrich
#2: CCAAGCACATCAGCCGTTT Sigma-Aldrich
#3: GAGGATGTGGGTTTACTCT Sigma-Aldrich
EGFR #1: GAGGAAATATGTACTACGA Sigma-Aldrich
#2: CTATGTGCAGAGGAATTAT Sigma-Aldrich
#3: GACATAGTCAGCAGTGACT Sigma-Aldrich
Rab5 ON-TARGET plus SMART pool Dharmacon
Rab11 ON-TARGET plus SMART pool Dharmacon
 
Table 4. List of siRNA.  
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2.5 Luciferase activity assay 
        Luciferase activity was measured following the instruction with a luciferase activity 
assay kit from Promega (Madison, WI). Briefly, cultured cells were lysed in lysis buffer 
provided in the kit. Cell lysates were cleared by centrifugation, and the supernatants 
were collected. Protein concentration was determined by Lowry protein assay. Protein 
samples (20 µg each in 20 µl of lysis buffer) were added into wells of an opaque-side, 
clear-bottom, 96-well microplate and then mixed with 80 µl in each well of the 
luciferase assay reagent. Luciferase activity was read immediately with a FLUOstar 
Omega luminescence microplate reader (BMG Labtech). 
2.6 MTT proliferation assay 
        Cells were cultured in 24-well plates with 0.5 mL/well of medium containing 0.5% 
FBS at 37°C. At the end of the desired treatment in cell culture, cells were incubated for 
an additional 2 hours after addition of 50 µL/well of 10 mg/mL 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT). Cells were then lysed with a lysis buffer 
(500 µL/well) containing 20% SDS in dimethyl formamide/H2O (1:1, v/v; pH 4.7) at 
37°C for at least 6 hours. The relative number of surviving cells in each group was 
determined by measuring the optical density (OD) of the cell lysates at an absorbance 
wavelength of 570 nm. The OD value in each treatment group was then expressed as a 
percentage of the OD value in the untreated control cells, and plotted against treatments. 
2.7 Clonogenic survival assay 
        In the experiments for radiation response, cells were seeded on 60-mm dishes and 
experienced irradiation at room temperature with γ-rays generated from a high-dose-rate 
137Cs unit (4.5 Gy/min). The irradiated cells were then sub-seeded in triplicate into 10-
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cm dishes, with densities varying from 500 to 3000 cells/dish according to the dose of γ-
rays the cells received (to yield 50–300 colonies per dish finally). In the experiments for 
responses to cetuximab and PDK1 targeting, the cells were seeded in triplicate into 6-cm 
dishes, with densities varying from 250 to 1000 cells/dish. The cells were cultured in a 
37 °C, 5% CO2 incubator for 8–20 days depending on the growth rate of the cells. 
Individual colonies (>50 cells/colony) were fixed and stained with a solution containing 
0.2% crystal violet in 10% ethanol for 30 minutes and counted. The surviving fraction, 
expressed as a function of irradiation, was calculated as follows: surviving fraction = 
colonies counted/(cell numbers seeded × plating efficiency), where plating efficiency is 
the percentage of cells seeded that grow into colonies under a specific culture condition 
of a given cell line. 
2.8 Metabolic flux assay 
        The bioenergetic flux of cells in response to cetuximab treatment or HIF-1α siRNA 
was determined using the Seahorse XF96 extracellular flux analyzer (Seahorse 
Biosciences). For cetuximab treatment, cells were plated at 2×104 cells/well in XF96 
plates and incubated at 37°C under conditions of 5% CO2 with DMEM/F12 cell culture 
medium containing 10% FBS for 24 hours. The medium was then changed to low serum 
(0.5% FBS) medium for serum starvation for another 24 hours. The cells were treated 
with and without 20 nM cetuximab for 10 hours in 0.5% FBS medium. The medium was 
then replaced with unbuffered DMEM XF assay medium (pH adjusted to 7.4 using 1N 
sodium hydroxide) supplemented with 2 mM glutamine and 1 g/L glucose, plus or minus 
20 nM cetuximab. For HIF-1α siRNA treatment, cells were experienced with control 
siRNA or HIF-1α siRNA as described in 2.4. After 48 hours, cells were plated at 2×104 
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cells/well in XF96 plates and incubated at 37°C under conditions of 5% CO2 with 
DMEM/F12 cell culture medium containing 10% FBS for another 24 hours. The 
medium was then replaced with the same unbuffered DMEM XF assay medium as 
described above. After medium changes, the cells were placed in a 37°C, CO2-free 
incubator for 1 hour. The basal oxygen consumption rate and extracellular acidification 
rate were then determined by using the XF96 plate reader with the standard program 
recommended by the manufacturer. 
2.9 Glucose consumption assay 
        Cells were seeded into 6-well plates at 5×105 cells/well in 3 mL of phenol-red-free 
cell culture medium containing 0.5% FBS and 1 g/L glucose. At indicated times after 
treatment, an aliquot of 50 µL of conditioned medium was collected from each well and 
diluted with 950 µL of distilled water (1:20). The glucose concentration in the diluted 
medium was measured using the Glucose (GO) assay kit from Sigma-Aldrich according 
to the manufacturer’s instructions. Briefly, samples were mixed with the glucose assay 
reagent provided in the assay kit and incubated at 37°C for 30 minutes. 12N sulfuric acid 
was added to each well to stop the reaction and OD values at 540 nm in each well were 
measured for comparison with the standard control of glucose. Glucose consumption 
was calculated by subtracting the concentration of glucose remaining in the medium at 
the indicated time point from the concentration of glucose present in fresh cell culture 
medium. Glucose consumption is expressed as mg/106 cells after indicated time periods. 
2.10 Lactate production assay 
        Cells were seeded into 6-well plates at 5×105 cells/well in 3 mL of serum-free cell 
culture medium containing 0.5% FBS and 1 g/L glucose. At indicated times after 
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treatment, an aliquot of 50 µL of conditioned medium was collected from each well and 
diluted with 950 µL of distilled water (1:20). The lactate concentration in the diluted 
medium was measured using the Lactate Assay Kit from BioVision Inc. (Milpitas, CA). 
Briefly, the sample was mixed with reaction reagent provided in the assay kit and 
incubated at 37 °C for 30 minutes before measurement of the OD value at 570 nm for 
comparison with the standard control of lactate. The levels of lactate are expressed as 
nmol/106 cells after indicated time periods. 
2.11 Intracellular ATP assay 
        Intracellular ATP levels were determined with the ATP bioluminescent assay 
(Sigma-Aldrich). Briefly, cells were seeded into 6-well plates at 5×105 cells/well and 
treated with or without 20 nM cetuximab for 4 hours in low-glucose (1 g/L) medium 
supplemented with 0.5% FBS. Cells were then harvested and resuspended in 1 mL of 
PBS. An aliquot of 50 µL of cell suspension was mixed with 100 µL of ATP-releasing 
reagent and 50 µL of water in each well of a 96-well plate. The samples (100 µL) in each 
well were then transferred to another 96-well plate pre-filled with 100 µL of ATP assay 
mix in each well. The amount of light emitted in each well was immediately measured 
under a luminometer (FLUOstar Omega). 
2.12 LDH-A activity assay 
        LDH-A activities were measured using a colorimetric LDH Activity Assay Kit 
(BioVision, Inc.) based on a reaction that converts NAD to NADH by LDH-A in a 
specific time period. Briefly, after desired treatments, cell pellets were collected and 
homogenized on ice in 0.5 mL of cold assay buffer. Supernatants were collected by 
centrifugation. Protein concentrations were determined by using the Pierce Coomassie 
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Plus colorimetric protein assay. 50 µL of aliquots (volume adjusted using assay buffer) 
containing equal amounts of protein and 50 µL of reaction reagent (48 µL of assay buffer 
and 2 µL of LDH-A substrate mix solution) were added into each well of a 96-well plate 
and the plates were read under a microreader at 450 nm immediately (T0) and 10 
minutes after the reaction (T1). LDH-A activity was expressed by an increase in OD 
values (T1-T0). Relative LDH-A activities in cells of untreated and treated groups were 
expressed as percentage of the LDH-A activity in cells of untreated group after 4 hours 
in culture, which was arbitrarily set as 100. 
2.13 Flow cytometry analysis for cell cycle 
        After desired treatments, cells were harvested by trypsin and fixed in 70% ethanol 
overnight. After centrifugation and washing with PBS, cells were stained with propidium 
iodide (50 µg/mL) and RNaseA (20 µg/mL) on ice for 30 minutes and then subjected to 
flow cytometric analysis with an LSRFortessa cell analyzer (BD Biosciences). Cell cycle 
distribution data were analyzed with FlowJo software, version 10. 
2.14 Cell death assay 
        Cell death was measured by using the Cell Death Detection ELISA, a colorimetric 
ELISA kit (Roche Diagnostics Corp., Indianapolis, IN) that quantitatively measures 
cytoplasmic histone-associated DNA fragments (mononucleosomes and 
oligonucleosomes). The procedure was performed exactly according to the 
manufacturer’s instructions. 
2.15 ROS detection 
        Intracellular ROS was measured by using the total ROS detection kit (Enzo Life 
Sciences, Plymouth Meeting, PA) according to the manufacturer’s instructions. Briefly, 
27 
 
cells were seeded in 12-well plate at around 40-60% confluency. After indicated 
treatment, cells were either stained directly with ROS detection solution at 37 °C for 1 
hour and analyzed using fluorescence microscopy equipped with standard green filter, or 
trypsinized and resuspended in eppendorf tubes, and stained with ROS detection solution 
at 37 °C for 1 hour and analyzed with an LSRFortessa cell analyzer (BD Biosciences). 
2.16 Mitochondrial membrane potential assay 
        Mitochondrial membrane potential (ψm) was measured by staining with fluorescent 
dye tetramethylrhodamine methyl ester (TMRM). For fluorescence microscopy, cells 
were seeded in 12-well plate at around 60-80 confluency. After indicated treatment, cells 
were stained with TMRM and counterstained with Hoechst at 37 °C for 30 minutes, and 
analyzed with fluorescence microscopy equipped with standard red and blue filter, 
respectively. For quantitative analysis, cells were seeded in clear-bottom, opaque-walled 
96-well plate at around 60-80 confluency. After indicated treatment, cells were stained 
with TMRM and counterstained with Hoechst at 37 °C for 30 minutes, and relative 
TMRM was determined by ratio of the reading at 590 nm (TMRM) over 460 nm 
(Hoechst) wavelength with a fluorescence plate reader.  
2.17 Glutamine uptake assay  
        After indicated treatment, cells were trypsinized and incubated with 0.5 mL of 
glutamine-deficient medium containing 5 µCi/mL radiolabelled 3H-glutamine at 37 °C 
for 5 minutes. After incubation, cells were spun down and washed three times with ice-
cold PBS, after which cells were lysed with 200 µL of a 0.2% SDS/0.2 N sodium 
hydroxide (NaOH) solution, incubated for 1 h, neutralized with 20 µL of 1 N 
hydrochloric acid (HCl), and analyzed with Beckman scintillation counter LS6500. 
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Relative glutamine uptake in cells of treated groups was expressed as percentage of the 
glutamine uptake in cells of untreated group.  
2.18 Intracellular glutathione assay 
        Intracellular glutathione was measured using glutathione assay kit (Cayman 
Chemical), based on the enzymatic recycling catalyzed by glutathione reductase and the 
reaction of GSH with 5,5′-dithio-bis-2-nitrobenzoic acid (DTNB) to produce a yellow 
product, which was quantified by a spectrometer. After indicated treatments, cells were 
collected, sonicated and deproteinated by precipitation with an equal volume of 10% 
metaphosphoric acid (Sigma-Aldrich). The precipitated proteins were removed by 
centrifugation at 3,000g for 5 min. The supernatant was collected, neutralized and 
assayed for GSH and GSSG using the Cayman glutathione assay kit according to the 
procedures recommended by the manufacturer. 
2.19 Immunoprecipitation 
        Indicated cells were lysed in a lysis buffer containing 50 mM TrisHCl (pH 7.4), 150 
mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl 
fluoride, 25 µg/ml aprotinin, and 25 µg/ml leupeptin and kept on ice for 15 min. The 
lysates were cleared by centrifugation, and the supernatants were collected. Protein 
concentration was determined as described in 2.3.  Protein extracts containing 500 µg 
protein were subsequently incubated for 1 hour at room temperature with the anti-EGFR 
monoclonal antibody cetuximab (4 µg), rabbit anti-ASCT2 antibody (4 µg), or with 
nonspecific normal mouse immunoglobulin G (IgG) (4 µg), and then incubated with 10 
µl protein A beads for 10 hours at 4 °C.  The precipitates were washed three times with a 
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lysis buffer and then denatured by heating in sample buffer. Immunoprecipitates were 
analyzed by Western blot as described for indicated antibodies as described in 2.3. 
2.20 Animal studies and imaging of tumor bioluminescence 
        Bioluminescent sublines of FaDu, FaDu-R, and UMSCC1 were established by 
infection with virus containing luciferase reporter gene. Female nude mice at 4-6 month 
old were inoculated with FaDu, FaDu-R, HN5, HN5-R, or UMSCC1 cells (1 × 107 
cells/mouse in 100 µl serum-free medium) subcutaneously on their right flanks. When 
tumors were well established at the volume of 150-250 mm3, the nude mice that had 
developed tumors were divided into six groups (6-7 mice in each group) with similar 
average tumor volume, and treated with vehicle, cetuximab (0.25 mg/mouse, bi-weekly), 
DCA (50 mg/kg/day or 250 mg/kg/day, daily), or combination of cetuximab and DCA 
for 21 days. Tumor volume was measured twice a week with a digital caliper, and 
calculated using the formula π/6 × ab2 (a: length; b: width, a > b). For bioluminescent 
sublines, tumors were also monitored using the Xenogen in vitro imaging system 
in living animals at day 21 from treatment start date, after intraperitoneal injection of D-
luciferin (3.3 mg/100 µl) and induction of anesthesia by inhalation of 2.5% isoflurane. 
After the end of treatment, measurement of tumor volume was continued in each group 
until the group had less than 4 mice.  
2.21 Statistical analysis 
        Student’s t-test was used in all statistical analyses. The data are presented as mean ± 
standard deviation in all in vitro experiments, and are presented as mean ± standard error 
of the mean in animal experiments. P values < 0.05 were considered statistically 
significant. 
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Chapter 3 Cetuximab sensitizes HNSCC to radiation through inhibiting radiation-
induced upregulation of HIF-1α 
  
3.1 Introduction 
        Radiation is an important therapy for patients with locally advanced and inoperable 
HNSCC. However, about 50% of patients treated with definitive radiotherapy with or 
without chemotherapy experience local recurrence or even remote metastasis [2, 78]. 
Because of prior radiotherapy, these patients usually cannot tolerate additional 
radiotherapy treatment, and most of whom eventually died of tumor local progression or 
remote metastasis with poor life qualities. Approximately 90% of HNSCCs express a 
high level of EGFR [17, 18]. Overexpression of EGFR confers HNSCC resistant to 
radiation [19-22, 79, 80]. Cetuximab improved the radiosensitivity of HNSCC in 
preclinical models [20, 32], and the combination of radiotherapy plus cetuximab resulted 
in prolonged survival in a pivotal phase III trial [23, 81]. Cetuximab has been approved 
by the Food and Drug Administration for treatment of HNSCC in combination with 
radiotherapy. However, the mechanisms underlying cetuximab-mediated 
radiosensitization of HNSCC are not fully understood.  
        Tumor hypoxia has been known to contribute to tumor radioresistance and poor 
clinical outcomes of human cancers for over half a century [38, 39]. During radiotherapy, 
oxygen is required to generate free oxygen radicals that induce DNA damage and kill 
tumor cells [82, 83]. Hypoxia-inducible factor-1 (HIF-1), the master regulator of tumor 
response to hypoxia, has recently been implicated in regulating radiation response in 
several preclinical and clinical studies [84-87]. Our lab previously reported that 
cetuximab downregulates HIF-1α, the regulatory subunit of HIF-1, by inhibiting new 
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HIF-1α protein synthesis [87]. Data from our lab also indicated that response of cancer 
cells to cetuximab correlates with downregulation of HIF-1α by cetuximab, and 
downregulation of HIF-1α by cetuximab is required to mediate cetuximab-induced 
antitumor activity [88, 89].  
        In this study, we hypothesized that cetuximab sensitizes HNSCC cells to radiation 
through inhibiting radiation-induced upregulation of HIF-1α. To test this hypothesis, we 
explored the effects of experimental elevation and experimental downregulation of HIF-
1α on radiation responses. We tested the effect of HIF-1α overexpression on anti-tumor 
roles of cetuximab as a monotherapy and in combination with radiotherapy. We also 
analyzed the impact of small molecular HIF-1α inhibitor in restoring the role of 
cetuximab in radiosensitization in cetuximab-resistant HNSCC cell lines. Our findings 
not only validated HIF-1α as an important target for sensitizing cetuximab plus 
radiotherapy, but also developed a novel strategy to improve the clinical response of 
HNSCC to radiotherapy.   
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3.2 Results 
3.2.1 Treatment with ionizing radiation upregulates HIF-1α through de 
novo protein synthesis in HNSCC cell lines 
        To examine whether radiation treatment can upregulate HIF-1α in HNSCC cell 
lines, two HNSCC cell lines, FaDu and HN5, both of which display inhibited 
proliferation in response to cetuximab treatment, were subjected to 3 Gy ionizing 
radiation for indicated time.  We found that the expression levels of HIF-1α were 
upregulated, examined by western blot analysis (Figure 7A),  and the transcriptional 
activities of HIF-1 were increased, examined by a hypoxia response element (HRE) 
luciferase reporter assay (Figure 7B) in both HN5 and FaDu cells after treatment of 
ionizing radiation in normoxic culture.  
        To investigate the mechanism underlying radiation-induced HIF-1α in HNSCC 
cells, we employed pharmacologic inhibitor of protein synthesis, cycloheximide, to 
determine its effect on HIF-1α expression in HN5 and FaDu cells after radiation 
treatment. We found that addition of cycloheximide immediately after radiation 
effectively inhibited radiation-induced regulation of HIF-1α expression (Figure 7C), 
suggesting that the radiation-induced upregulation of HIF-1α involves de novo protein 
synthesis. 
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3.2.2 Overexpression of HIF-1α renders HNSCC cells radio-resistant, whereas 
silencing of HIF-1α sensitizes HNSCC cells to radiation 
        To determine the role of HIF-1α in mediating cell response to radiation, we 
examined cell responses to radiation through experimentally changing the level of HIF-
1α in HN5 and FaDu cells. Since wild-type HIF-1α is instable in normoxia, we 
transfected HN5 and FaDu cells with a HIF-1α mutant with deletion of the oxygen-
dependent degradation domain (HIF-1α-∆ODD), which is degradation-resistant in 
normoxic culture and retains the majority of transcriptional activity of HIF-1α. We 
found that overexpression of HIF-1α-∆ODD conferred resistant to radiation in both HN5 
and FaDu cells, as measured by clonogenic survival assays (Figure 8A and B). In 
contrast, silencing of HIF-1α expression by HIF-1α siRNA for 48 h before radiation 
treatment sensitized responses to radiation in HN5 and FaDu cells (Figure 8C and D). 
These findings indicated that HIF-1α plays an important role in conferring resistance to 
radiation. 
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3.2.3 Cetuximab inhibits radiation-induced upregulation of HIF-1α in HNSCC cells, 
leading to radiosensitization 
        Next we tested whether cetuximab sensitizes cancer cells to radiation through 
inhibiting radiation-induced HIF-1α upregulation. Compared to the effect with radiation 
treatment alone, addition of cetuximab after radiation treatment substantially enhanced 
radiation-induced inhibition of clonogenic survival in HN5 and FaDu cells (Figure 9A), 
which is consistent with literature. Figure 9B and 9C showed that addition of cetuximab 
after radiation downregulated the expression level and inhibited the activity of radiation-
induced HIF-1α.  
        To determine whether downregulation of HIF-1α is required for cetuximab-
mediated radiosensitization, we established HN5 and FaDu cells stably expressing HIF-
1α-∆ODD. Overexpression of HIF-1α-∆ODD conferred substantial resistance to 
cetuximab treatment alone in both HN5 and FaDu cells (Figure 9D). Figure 9E showed 
that in both HN5 and FaDu cells, overexpression of HIF-1α-∆ODD strongly abolished 
cetuximab-mediated radiosensitization that was observed in the parental cells (see Figure 
9A). There were no significant differences in the clonogenic survivals between groups 
with or without addition of cetuximab after radiation in HN5-HIF-1α-∆ODD and FaDu-
HIF-1α-∆ODD cells. These data suggested that cetuximab-induced inhibition of HIF-1α 
is critical in cetuximab-mediated radiosensitization of HNSCC cells. 
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3.2.4 Silencing of HIF-1α improves radiosensitization by cetuximab and overcomes 
oncogenic H-Ras-mediated radiation resistance 
        To explore whether silencing HIF-1α may sensitize HNSCC cells to radiation, we 
employed both cetuximab-sensitive cell lines HN5 and FaDu, in which HIF-1α was 
strongly downregulated by cetuximab, and cetuximab-resistant cell lines UMSCC1 and 
OSC19. Although UMSCC1 and OSC19 contain EGFR levels similar to FaDu cells, 
they were resistant to HIF-1α downregulation by cetuximab (Figure 10). Cetuximab 
failed to downregulate HIF-1α protein levels either in HN5 and FaDu cells transfected 
with a constitutively active H-Ras mutant (H-Ras G12V) (Figure 10). Figure 11A shows 
that pre-treatment with HIF-1α siRNA strongly increased responses to cetuximab in 
UMSCC1 and OSC19 cells. The inhibition rate to cetuximab increased from ∼20% 
(UMSCC1) and ∼10% (OSC19) in control siRNA groups to ∼50% (UMSCC1) and ∼40% 
(OSC19) in HIF-1α siRNA groups. Similar results were observed in the HN5 and FaDu 
cells that were transfected for stable expression of H-Ras G12V (Figure 11C). 
Experimental expression of H-Ras G12V in HN5 and FaDu cells not only caused the 
failure of cetuximab in downregulating HIF-1α protein levels, but also conferred 
considerable resistance to cetuximab-induced growth inhibition in control siRNA-treated 
HN5-RasG12V cells (<10% inhibition) and FaDu-RasG12V cells (only 10–20% 
inhibition). Pre-treatment with HIF-1α siRNA resensitized responses to cetuximab in 
HN5-RasG12V and FaDu-RasG12V cells by increasing inhibition rate to 50-60% and 
40-50%, respectively.  
        HIF-1α silencing not only increased response to cetuximab in cetuximab-resistant 
cells, but more importantly, also restored the role of cetuximab in radiosensitization. As 
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measured by clonogenic survival assay, cetuximab failed to sensitize UMSCC1 or 
OSC19 cells to radiation; however, cetuximab substantially sensitized HIF-1α-silenced 
UMSCC1 and OSC19 cells to radiation (Figure 11B). Similar results were observed in 
HN5-RasG12V and FaDu-RasG12V cells. Cetuximab substantially sensitized HIF-1α-
silenced, but not control siRNA-transfected, HN5-RasG12V and FaDu-RasG12V cells to 
radiation (Figure 11D). These results indicated a critical role of cetuximab-induced 
downregulation of HIF-1α in both the response of cells to cetuximab-induced 
proliferation inhibition and radiosensitization. 
    
            
Figure 10. Cetuximab downregulates HIF-1α protein levels in sensitive, but 
not in resistant HNSCC cell lines. The indicated HNSCC cell lines (FaDu, HN5, 
OSC19, UMSCC1, and FaDu and HN5 cells transfected with H-Ras G12V) were 
cultured in the presence or absence of 20 nM cetuximab for 16 h, and then the 
cells were collected for detection of the levels of HIF-1α and EGFR protein by 
Western blot analysis. The level of β-actin was used as an internal control of 
equal protein loading in each lane.   
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Figure 11. Silencing HIF-1α enhances responses of cetuximab-resistant 
HNSCC cells to cetuximab-induced growth inhibition and radiosensitization. 
(A) and (B) UMSCC1 and OSC19 cells were transiently transfected with HIF-
1α-specific siRNA or control siRNA for 48 h. The cells were then assayed for 
responses to cetuximab treatment for 5 days by MTT assays (A) and for 
responses to treatment with ionizing radiation in the presence and absence of 10 
nM cetuximab for 14 days by clonogenic survival assays (B). (C) and (D) HN5-
RasG12V and FaDu-RasG12V cells were similarly transfected with HIF-1α 
siRNA or control siRNA for 48 h and subjected to MTT assays (C) and 
clonogenic survival assays (D) for response to treatment with cetuximab and 
ionizing radiation as described in (A) and (B). Cetu, cetuximab; siHIF-1α, HIF-
1α siRNA.   
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3.2.5 The combination of cetuximab and 1-methyl 1, 9 PA sensitizes HNSCC cells to 
radiation 
        Our previous work showed that 1-methyl 1, 9 PA, a small molecule compound that 
is a derivative of anthrapyrazolone, downregulates HIF-1α protein levels and is a 
potential HIF-1 inhibitor [90]. We thus evaluated whether addition of 1-methyl 1, 9 PA 
can sensitize UMSCC1 and OSC19 cells to cetuximab and cetuximab plus radiation 
treatment. It has been reported that 1-methyl 1, 9 PA alone at a dose of 10 µM can 
strongly downregulate HIF-1α in various types of cancer cells. Figure 12A shows that 
addition of 10 µM 1-methyl 1, 9 PA significantly increased responses to cetuximab in 
cetuximab-resistant UMSCC1 and OSC19 cells (p < 0.01). Figure 12B shows that the 
combination of cetuximab and 1-methyl 1, 9 PA increased the sensitivity of UMSCC1 
and OSC19 cells to radiation, while either agent alone did not enhance the responses to 
radiation. These results from this pilot study provide a novel concept that inhibition of 
HIF-1α with a small molecule compound may improve response of cetuximab-resistant 
HNSCC cells to treatment with the combination of radiation and cetuximab. 
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3.3 Discussion 
        In this part, our major findings are: (1) Ionizing radiation upregulates HIF-1α 
through de novo protein synthesis in HNSCC cells; (2) Cetuximab inhibits radiation-
induced HIF-1α upregulation; (3) Inhibition of HIF-1α by siRNA or small molecular 
compound increases responses to cetuximab and cetuximab plus radiation. Consistent 
with the findings reported in the literature for other types of cancers [91-93], our data 
confirm that ionizing radiation can upregulate HIF-1α in HNSCC cells irrespective to 
hypoxia. These findings suggest a novel strategy by targeting HIF-1α to enhance the 
response of HNSCC cells to treatment with the combination of radiation and cetuximab. 
        Radiation is a major treatment modality for patients with locally advanced and 
inoperable head and neck cancer. However, about 50% of patients treated with definitive 
radiotherapy with or without chemotherapy go onto experience local recurrence or even 
remote metastasis [2, 78]. Cetuximab is approved by FDA for enhancing the response of 
HNSCC to radiation. Although in clinical trials, combination of cetuximab and 
radiotherapy showed prolonged survival, there are multiple mechanisms in HNSCC that 
can render cancer cells resistant to cetuximab as a monotherapy or in combination with 
radiation. Common resistance mechanisms to cetuximab include constitutive activation 
of EGFR downstream signals, such as oncogenic activation of H-Ras mutant (in contrast 
to K-Ras mutation in colorectal cancers), mutational inactivation of tumor suppressors, 
such as PTEN, or cross-activation of EGFR downstream signaling pathways by other 
growth factor receptors in the same family (e.g., HER2, HER3) or different families (e.g., 
IGF-1R) or through tumor-stromal interactions [94-96]. Previous work in our lab 
showed that HIF-1α is one of the most important effector molecules downstream of 
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EGFR pathway and downregulation of HIF-1α by cetuximab is required for cetuximab’s 
anti-tumor effect [88-90, 97]. Our work in this part expanded the serial studies in our lab 
demonstrating the role of downregulating HIF-1α in mediating cetuximab-induced 
antitumor activities and suggesting a novel approach of co-targeting HIF-1α to overcome 
resistance of cancer cells to cetuximab monotherapy or in combination with radiation.  
        HIF-1 has been suggested to play an important role in tumor radioresistance. 
However, the mechanisms through which irradiation regulates HIF-1α expression remain 
unclear. One of the mechanisms reported in the literature by which HIF-1α is 
upregulated by irradiation is radiation-induced tumor reoxygenation [91]. However, in 
this study, we found that HIF-1α can be upregulated independent of tumor 
reoxygenation, as the cells were cultured in vitro in normoxia. Our observation that 
upregulation of HIF-1α by radiation involves de novo protein synthesis in head and neck 
cancer cell models is consistent with a recent study in lung cancer cell models. Kim et al. 
reported that radiation induced HIF-1α protein expression mainly through two distinct 
pathways, including activation of PI3K/Akt/mTOR, which leads to stimulation of de 
novo synthesis of HIF-1α, and stimulation of Hsp90 function, which leads to 
stabilization of HIF-1α protein [92]. Our finding indicates that there are multiple 
mechanisms by which HIF-1α is upregulated after radiation. 
        Although overexpression of HIF-1α caused by tumor hypoxia or aberrant signaling 
in cancer cells have been reported to be associated with a poor response to radiation [91, 
92, 98-102], the impact of radiation-induced HIF-1α upregulation on tumor response to 
radiation is not clear. The impact of radiation-induced upregulation of HIF-1α on overall 
tumor radiosensitivity is pleiotropic: by promoting ATP metabolism, cell proliferation 
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and p53 activation, HIF-1 has a radiosensitizing effect on tumors; however, through 
stimulating endothelial cell survival, HIF-1 promotes tumor radioresistance [103]. Our 
findings derived from clonogenic survival assays performed in cell culture, support a 
conclusion that at least in HNSCC cells, HIF-1 has a net role of promoting 
radioresistance. Upregulation of HIF-1α conferred radioresistance whereas silencing of 
HIF-1α sensitized cancer cells to radiation. Our data also expand understanding of 
antitumor effect of cetuximab that downregulation of HIF-1α by cetuximab plays an 
important role in cetuximab-mediated radiosensitization. However, in vivo experiments 
are needed to further confirm the exact role of inhibition of radiation-induced HIF-1α 
upregulation in cetuximab-mediated radiosensitization. Results from in vivo experiments 
may provide further guidance for designing novel therapeutic strategies by targeting 
HIF-1 to enhance clinical responses to combination treatment of cetuximab and radiation 
in head and neck cancer.  
        In summary, our results in this part show that downregulation of HIF-1α contributes 
to cetuximab-mediated radiosensitization in HNSCC cells and indicate that targeting 
HIF-1α is a promising strategy for sensitizing cetuximab-resistant HNSCC cells to 
combination of cetuximab and radiation. 
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Chapter 4 Cetuximab inhibits aerobic glycolysis and reverses Warburg effect in 
HNSCC via inhibition of HIF-1-regulated LDHA 
 
4.1 Introduction 
        Glucose is considered to be the most important energy and carbon source for both 
nontransformed and transformed cells. It has been observed for many years that cancer 
cells have different glucose metabolic pattern with normal cells. normal cells metabolize 
glucose mainly via a low rate of glycolysis followed by oxidative phosphorylation in the 
mitochondria through the tricarboxylic acid cycle, while cancer cells prefer to 
metabolize glucose by a high rate of glycolysis followed by lactate production in the 
cytosol even when oxygen is abundant, a phenomenon known as aerobic glycolysis or 
the “Warburg effect” [54, 104]. Because of the low efficiency of glycolysis in generating 
ATP, the reliance of tumor cells on glycolysis cause them to consume more glucose 
[105]. Aerobic glycolysis is important for cancer cell proliferation not only because this 
process provides the energy needed by cells to survive and perform various functions but 
more importantly because this process generates building blocks and reducing power, 
both of which are needed for cellular biosynthesis fueling cell growth and proliferation 
[106, 107]. Although the molecular mechanisms underlying the Warburg effect has not 
been fully understood yet, the altered glucose metabolism has been reported to be 
correlated directly with aberrant cell signaling caused by overexpression of growth 
factor receptors, activation of oncogenes, and/or inactivation of tumor suppressor genes 
to permit unlimited cancer cell proliferation [105-109].   
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        The transcription factor HIF-1 plays a key role in reprogramming cancer cell 
metabolism from oxidative phosphorylation towards aerobic glycolysis through 
regulating expression of the genes coding for proteins involved in various steps of cancer 
metabolism including glucose transporters, glycolytic enzymes, and lactate transporters. 
Most importantly, HIF-1 activates lactate dehydrogenase A (LDH-A), the enzyme that 
catalyzes conversion from pyruvate to lactate [62]; and activates pyruvate 
dehydrogenase kinase 1 (PDK1), which phosphorylates and negatively regulates 
pyruvate dehydrogenase (PDH), the gatekeeper of tricarboxlic acid cycle [64]. Thus, 
activation of HIF-1 contributes to Warburg effect and mediates a glucose metabolic 
transition from oxidative phosphorylation towards glycolysis. HIF-1 has been reported to 
be overexpressed in many types of cancers, including colon, breast, gastric, lung, skin, 
ovarian, pancreatic, prostate, and renal carcinomas [110-112]. The high level of HIF-1α 
in cancer cells is caused not only by decreased ubiquitination and degradation of HIF-1α 
protein via a posttranslational mechanism associated with tumor hypoxia [44, 45] but 
also by increased expression of HIF-1α protein via a translational mechanism as a result 
of aberrant cell signaling [48-50, 113, 114]. 
        Our work in Chapter 3 as well as previous work in our lab showed that cetuximab 
inhibits expression and function of HIF-1 through inhibition of the PI3K/Akt and 
MEK/Erk pathways, and this downregulation of HIF-1 by cetuximab is required, 
although may not be sufficient, for its anti-tumor effect [97, 115, 116]. Our work in 
Chapter 3 also showed that inhibition of HIF-1α by siRNA or small molecular inhibitor 
overcame resistance of cancer cells to cetuximab treatment as a monotherapy or in 
combination with radiation. Although the importance of HIF-1α downregulation in 
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mediating cetuximab-induced antitumor effects is well established, however, no studies 
so far have carefully examined the mechanism underlying growth inhibition after 
downregulation of HIF-1α by cetuximab. In this chapter, we hypothesized that 
cetuximab inhibits cancer cell proliferation through inhibition of glycolysis by 
downregulating HIF-1α, thereby reversing the Warburg effect that is critically important 
for cancer cell survival and proliferation.  To test this hypothesis, we analyzed the 
impact of cetuximab treatment on changes in the two major energy-producing pathways 
of cells, glycolysis and mitochondrial respiration using the Seahorse XF96 extracellular 
flux analyzer in cetuximab sensitive and genetic matched acquired resistant HNSCC cell 
lines. We measured the effect of cetuximab on the expression and enzymatic activity of 
LDH-A, which regulates the conversion of pyruvate to lactate, and on the levels of 
glucose consumption, lactate production, and intracellular ATP in cetuximab-sensitive 
and cetuximab-resistant cells. Findings in this chapter provide novel insights into the 
mechanisms underlying cetuximab-induced antiproliferative and apoptotic effects in 
cancer cells and suggest a novel therapeutic strategy for improving the response of 
cancer patients to cetuximab treatment. 
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4.2 Results 
4.2.1 Acquired resistance to cetuximab is not linked to the failure of cetuximab to 
inhibit EGFR downstream cell signaling  
        To study different responses to cetuximab between parental and cetuximab-
acquired resistant HNSCC cells, we first generated two pairs of isogenic cetuximab-
sensitive and cetuximab-resistant HNSCC cell lines by subjecting cetuximab-sensitive 
HN5 and FaDu cells to cetuximab-containing media in continuous culture for more than 
1 year with stepwise increases in concentration up to 20 nM, which is approximately 10 
times the Kd of cetuximab for binding to EGFR [26]. Figure 13A showed that the 
resultant sublines, termed HN5-R and FaDu-R respectively, were more resistant to 
cetuximab compared with parental HN5 and FaDu cells. HN5 cells have higher protein 
levels of EGFR and HIF-1α than FaDu cells. In both HN5 and FaDu cells, the protein 
levels of HIF-1α were decreased by cetuximab (Figure 13B). In contrast, HN5-R and 
FaDu-R cells exhibited higher levels of HIF-1α than their respective parental cells, and 
the effect of cetuximab in decreasing levels of HIF-1α in HN5-R and FaDu-R cells were 
minimal. Levels of LDH-A were decreased by cetuximab only in parental HN5 and 
FaDu cells but not in HN5-R and FaDu-R cells. Interestingly, HN5-R and FaDu-R cells 
remained sensitive or partially sensitive to cetuximab-induced inhibition of cell signaling, 
shown by inhibition of EGFR autophosphorylation and reduced phosphorylation of Akt-
S473 and Erk T202/Y204, two important signaling molecules downstream of EGFR 
(Figure 13B). These novel findings suggested that acquired resistance to cetuximab may 
not be linked to the failure of cetuximab in inhibiting EGFR downstream signals.  
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Figure 13. Acquired resistance to cetuximab is not linked to the failure of 
cetuximab to inhibit EGFR downstream cell signaling. (A) HN5 and FaDu 
cells and their cetuximab-resistant sublines (HN5-R and FaDu-R) selected after 
long-term exposure to cetuximab were treated with cetuximab at the indicated 
doses for 5 days in 0.5% FBS medium. Cell growth responses to cetuximab were 
measured by an MTT assay. (B) The indicated cells were left untreated or treated 
with 20 nM cetuximab for 24 hours. Cell lysates were prepared, and equal 
amounts of cell lysates were subjected to Western blot analysis with the indicated 
antibodies. 
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4.2.2 Cetuximab inhibits aerobic glycolysis, and resistance to cetuximab is linked to 
increased glycolytic flux 
        To further analyze the metabolic changes after cetuximab treatment, we employed 
the Seahorse XF96 extracellular flux analyzer to record metabolic profiles with and 
without cetuximab treatment in cetuximab-sensitive and cetuximab-resistant cell lines.  
Compared to the parental HN5 and FaDu cells, the cetuximab-resistant HN5-R and 
FaDu-R cells had higher levels of aerobic glycolysis, indicated by higher extracellular 
acidification rates (ECAR, black lines versus red lines in Figure 14). Furthermore, 
cetuximab decreased ECAR and increased oxygen consumption rate (OCR, blue lines 
versus red lines) in parental HN5 and FaDu cells, but not in HN5-R and FaDu-R cells 
(black lines versus green lines). It is noteworthy that after challenge of the cells with 
oligomycin, an ATP synthase inhibitor, the oxygen consumption rate in both the parental 
and cetuximab-resistant cell lines, particularly the resistant sublines, did not decrease 
significantly, indicating that the metabolic pattern of these cells are highly glycolytic. 
After challenge of the cells with FCCP, an uncoupler of oxidative phosphorylation and 
ATP synthesis, the resistant cell lines had higher capacity to increase ECAR than the 
parental cells. This finding is consistent with the higher HIF-1α and LDH-A levels in the 
resistant sublines than in the parental cells.  
        Taken together with 4.2.1, these novel findings indicate that LDH-A was 
downregulated and Warburg effect was reversed by cetuximab in cetuximab-sensitive 
HNSCC cells but not in the resistant sublines. The resistant sublines exhibited increased 
levels of HIF-1α as well as increased glycolytic potential. 
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Figure 14. Cetuximab inhibits glycolytic flux in cetuximab-sensitive, but not 
acquired-resistant HNSCC cells. HN5, HN5-R, FaDu, and FaDu-R cells were 
left untreated or treated with 20 nM cetuximab for 10 hours, and metabolic flux 
analysis was performed to measure changes in extracellular acidification rate 
(ECAR) and oxygen consumption rate (OCR). 
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4.2.3 High level of HIF-1α are directly related with increased glycolysis in 
cetuximab acquired resistant cells 
        To further confirm a direct role of high level of HIF-1α in promoting aerobic 
glycolysis  in HN5-R and FaDu-R cells, we knocked down HIF-1α in the cells and found 
that level of LDH-A was markedly decreased in both parental and the cetuximab-
resistant sublines (Figure 15A). Knockdown of HIF-1α also induced significant 
decreases of ECAR and increases of OCR in HN5-R and FaDu-R cell lines (Figure 15B).  
 
Figure 15. Knockdown of HIF-1 downregulates LDH-A and reverse 
Warburg effect. (A) HN5, HN5-R, FaDu, and FaDu-R cells were subjected to 
knockdown of HIF-1α by siRNA, followed by Western blotting with indicated 
antibodies. (B) HN5-R and FaDu-R cells were treated with each of 2 pairs of 
HIF-1 siRNA or control siRNA for 48 hours and metabolic flux analysis was 
performed to measure changes in ECAR and OCR.   
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4.2.4 Cetuximab reduces glucose consumption, lactate production and intracellular 
ATP level in a HIF-1α downregulation-dependent manner 
        To further confirm the inhibition of aerobic glycolysis by cetuximab we found in 
4.2.2, we directly measured consumption of glucose and production of lactate after 
cetuximab treatment in HN5 and FaDu cells, and found that cetuximab inhibited glucose 
consumption and lactate production in a time-dependent manner (Figure 16A and B). To 
elucidate the mechanism through which cetuximab inhibits glycolysis, we transfected 
HN5 and FaDu cells with HIF-1α-∆ODD. As described in 3.2.2, this mutant retains the 
majority of the transcriptional activity of full-length HIF-1α and can be stably 
overexpressed in normoxic culture. Consistent with the knowledge that HIF-1 promotes 
aerobic glycolysis, overexpression of HIF-1α-∆ODD in HN5 and FaDu cells (HN5- 
HIF-1α-∆ODD and FaDu- HIF-1α-∆ODD cells) significantly increased the levels of 
glucose consumption and lactate production and conferred resistance to cetuximab 
mediated inhibition of glucose consumption and lactate production. 
        We also measured the changes of intracellular ATP levels after cetuximab treatment 
for a short time (4 hours) in HN5 and FaDu cells transfected with control vectors or with 
HIF-1α-∆ODD (Figure 16C). No changes in cell numbers were detected at 4 hours after 
treatment between cells treated and not treated with cetuximab. In HN5 and FaDu cells, 
cetuximab substantially decreased intracellular ATP levels (39% and 31%, respectively). 
In contrast, in HN5-HIF-1α-∆ODD and FaDu-HIF-1α-∆ODD cells, only modest 
decreases in the ATP levels (15% and 11%, respectively) were observed between after 
cetuximab treatment. Taken together, these findings showed that cetuximab inhibits 
glycolysis in a HIF-1α inhibition dependent manner.  
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Figure 16. Cetuximab inhibits glucose consumption, lactate production, and 
intracellular ATP levels in a HIF-1α inhibition-dependent manner. (A) HN5, 
HN5-HIF-1α-∆ODD, FaDu, and FaDu-HIF-1α-∆ODD cells were seeded into 6-
well plates with 3 mL of low glucose (1 g/L) medium supplemented with 0.5% 
FBS. The cells were treated with 20 nM cetuximab or not as indicated. At each 
time point after treatment, the level of glucose remaining in the conditioned 
medium was determined with an assay described in materials and methods. (B) 
The indicated cells were seeded and treated similarly as described in (A). At each 
time point after treatment, the level of lactate produced in the conditioned 
medium was determined with an assay described in materials and methods. (C) 
The indicated cells were left untreated or treated with 20 nM cetuximab in low-
glucose (1 g/L) medium supplemented with 0.5% FBS for 4 hours. Cell pellets 
were harvested, and the intracellular level of ATP was measured with a luciferase 
based ATP determination assay as described in Materials and Methods. The 
relative values of ATP in treated groups were expressed as a percentage of the 
value of ATP in corresponding untreated groups. 
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4.2.5 Cetuximab inhibits LDH-A expression and enzymatic activity through 
downregulation of HIF-1α 
        To further elucidate the biochemical mechanisms through which cetuximab inhibits 
glycolysis via downregulation of HIF-1α, we studied the changes of LDH-A, a direct 
target of HIF-1 transcription factor, after cetuximab treatment in different time points. 
We compared the effect of cetuximab on downregulation of LDH-A and on EGFR 
downstream signaling pathways between HN5 and HN5-HIF-1α-∆ODD cells and 
between FaDu and FaDu-HIF-1α-∆ODD cells. We found that cetuximab treatment 
downregulated the protein levels of LDH-A in both HN5 and FaDu cells but not in HN5-
HIF-1α-∆ODD and FaDu-HIF-1α-∆ODD cells (Figure 17A). Interestingly, the 
phosphorylation levels of Akt and Erk were still sensitive to cetuximab in HN5-HIF-1α-
∆ODD and FaDu-HIF-1α-∆ODD cells. This is consistent with phosphorylation levels of 
these molecules after cetuximab treatment in HN5-R and FaDu-R cells, as described in 
4.2.1.   
        Consistent with the decrease in LDH-A protein levels in HN5 and FaDu cells 
induced by cetuximab, the activity of LDH-A in catalyzing the production of lactate was 
also decreased in these cells, as early as 4 hours after cetuximab treatment (Figure 17B). 
Overexpression of HIF-1α-∆ODD significantly increased the enzymatic activity of 
LDH-A, and abolished the effect of cetuximab in inhibiting LDH-A activity. Taken 
together, these findings showed that cetuximab downregulates LDH-A expression and 
inhibits LDH-A activity via downregulation of HIF-1α, leading to inhibition of 
glycolysis. 
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Figure 17. Cetuximab downregulates LDH-A expression and reduces LDH-
A activity in a HIF-1α inhibition-dependent manner. HN5 and FaDu cells 
expressing control vector or HIF- 1α-∆ODD were left untreated or treated with 
20 nM cetuximab for the indicated time periods. (A) Cell lysates were prepared, 
and equal amounts of cell lysates were subjected to Western blot analysis with 
the indicated antibodies. (B) Cells were harvested and homogenized, and samples 
containing equal amounts of proteins were subjected to an LDH-A activity assay 
as described in materials and methods. 
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4.2.6 Knockdown of LDH-A overcomes resistance to cetuximab-induced G1 arrest 
        Aerobic glycolysis has been suggested to be a means of fueling cancer cells with 
energy and biomass needed for proliferation [117]. To find the correlation between 
cetuximab-induced inhibition of glycolysis through downregulating HIF-1α and LDH-A 
and the effect of cetuximab in inhibiting cancer cell proliferation, we performed cell 
cycle analysis after treatment with cetuximab and LDH-A siRNA, alone and in 
combination. To avoid off-target effect of LDH-A, three different LDH-A-specific 
siRNA were tested in our experiments, all of which successfully knocked down the level 
of LDH-A in all four cell lines (Figure 18A, C, and E). LDH-A siRNA #1 and #2 were 
used for knockdown of LDH-A in the cells for cell cycle analysis. 
        Treatment of HN5 and FaDu cells with cetuximab increased the percentage of cells 
in G1 phase from 67.9% to 85% in HN5 cells and from 64.9% to 83.2% in FaDu cells 
(Figure 18B). Knockdown of LDH-A expression alone by siRNA #1 modestly increased 
the percentage of G1 phase cells from 67.9% to 73% in HN5 cells and 64.9% of 70.2% 
in FaDu cells. The combination of cetuximab and LDH-A knockdown had an additive 
effect on G1 arrest, increasing the percentage of G1 phase cells to 90.3% in HN5 cells 
and 87.1% in FaDu cells. Similar results were confirmed by using LDH-A siRNA #2 
(Figure 19). 
        Compared with HN5 and FaDu cells, both the acquired resistant sublines and the 
HIF-1α-∆ODD-overexpressing cell lines showed increases in the percentage of 
proliferating cells. The percentage of cells in G2/M phase increased from 24% in HN5 
cells to 33.9% and 39.4% in HN5-R and HN5-HIF-1α-∆ODD cells respectively and 
from 22.3% in FaDu cells to 28.1% and 27.7% in FaDu-R and FaDu-HIF-1α-∆ODD 
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cells respectively (Figure 18B, D, and F). These cells were also resistant to cetuximab-
induced G1 arrest. Cetuximab failed to increase the percentage of G1 phase cells in 
either acquired resistant sublines or HIF-1α-∆ODD-overexpressing cell lines. Since both 
HN5-R and FaDu-R have much higher HIF-1α levels compared with their parental 
counterpart, this finding is consistent with the role of HIF-1α in counteracting 
cetuximab-induced inhibition of glycolysis and downregulation of LDH-A. Knockdown 
of LDH-A by siRNA #1 largely restored the activity of cetuximab in inducing G1 cell 
cycle arrest in these cells: compared to cetuximab alone, the combination of cetuximab 
and LDH-A knockdown increased the percentage of G1 phase cells from 54.0% to 72.3% 
in HN5-R cells, from 52.5% to 84.7% in HN5-HIF-1α-∆ODD cells, from 60.7% to 76.5% 
in FaDu-R cells, and from 67.9% to 83.0% in FaDu-HIF1α-∆ODD cells. Similar results 
were confirmed by using LDH-A siRNA #2 (Figure 19). These findings confirm the role 
of HIF-1α in cetuximab-induced cell cycle arrest and suggest LDH-A as a good target to 
improve cancer cell response to cetuximab treatment. 
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Figure 18. Knockdown of LDH-A overcomes resistance to cetuximab-
induced G1 arrest. (A), (C) and (E) The indicated cells were subjected to 
knockdown of LDH-A with three different LDH-A-specific siRNA or control 
siRNA in low-glucose (1 g/L) and low-serum (0.5% FBS) medium for 48 hours. 
Cell lysates were prepared, and equal amounts of cell lysates were subjected to 
Western blot analysis with the indicated antibodies. (B), (D) and (F) The 
indicated cells were treated with LDH-A siRNA #1 or control siRNA as 
described in (A), (C) and (E). The cells were then left untreated or treated with 
20 nM cetuximab for 24 hours, followed by fixation and propidium iodide 
staining for cell cycle distribution analysis by flow cytometry. The data presented 
are mean ± SD. 
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Figure 19. Knockdown of LDH-A overcomes resistance to cetuximab-
induced G1 arrest. The indicated cells were treated with LDH-A siRNA #2 or 
control siRNA for 48hours, and then left untreated or treated with 20 nM 
cetuximab for 24 hours, followed by fixation and propidium iodide staining for 
cell cycle distribution analysis by flow cytometry. The data presented are mean ± 
SD. 
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4.2.7 Knockdown of LDH-A potentiates cetuximab to induce apoptosis but fails to 
overcome cetuximab resistance through inducing apoptosis 
        To determine whether knockdown of LDH-A can potentiate induction of apoptosis 
in addition to G1 cell cycle arrest by cetuximab, we examined induction of apoptosis 
using two independent apoptosis assays (PARP cleavage and DNA fragmentation) in the 
HN5 series (parental HN5, HN5-R, and HN5-HIF-1α-∆ODD cells) and FaDu series 
(parental FaDu, FaDu-R, and FaDu-HIF-1α-∆ODD cells) after treatment with cetuximab 
and knockdown of LDH-A, alone and in combination. The combination treatment 
resulted in an additive effect on decreasing the levels of LDH-A in parental HN5 and 
FaDu cells, but not in HN5-R and FaDu-R cells or in HN5-HIF-1α-∆ODD and FaDu-
HIF-1α-∆ODD cells (Figure 20A). Compared with either single treatment alone, the 
combination treatment induced apoptosis in HN5 and FaDu cells but only had minimal 
such effect in the acquired resistant sublines and the HIF-1α-∆ODD-overexpressing cells 
(Figure 20A and B). These findings indicate that while knockdown of LDH-A can 
potentiate cetuximab to induce apoptosis, it alone may not be sufficient to induce 
apoptosis or to overcome cetuximab resistance to induce apoptosis when used in 
combination with cetuximab. 
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Figure 20. Knockdown of LDH-A minimally potentiates induction of 
apoptosis by cetuximab. The indicated cells were subjected to knockdown of 
LDH-A with specific siRNA or control siRNA for 48 hours and then treated with 
20 nM cetuximab or not as indicated for 24 hours in low glucose (1 g/L) and low 
serum (0.5% FBS) medium. (A) After treatment, cell lysates were prepared, and 
equal amounts of cell lysates were subjected to Western blot analysis with the 
indicated antibodies. Quantification of the LDH-A and cleaved PARP bands was 
performed with ImageJ software and the data were expressed as fold increases in 
reference to the leftmost lane of the blots, the value of which was arbitrarily set 
as 1. (B) The same cell lysates as in (A) were analyzed for the level of DNA 
fragmentation with an apoptosis ELISA kit as described in materials and methods. 
The data in the treated groups were expressed as fold increases in the optical 
density value compared to the value in corresponding untreated cells. 
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4.2.8 Combination of cetuximab and LDH-A inhibitor oxamate effectively inhibit 
cell proliferation in cetuximab resistant cancer cells 
        To further confirm LDH-A as a target to increase cetuximab response and to 
overcome cetuximab resistance, we examined the effects of a small molecule inhibitor of 
LDH-A, oxamate [118], alone and in combination with cetuximab on growth and 
survival of HNSCC cells after 5-day extended culture (Figure 21). MTT assays, which 
collectively measure the effects of cell cycle arrest and induction of apoptosis, showed 
that combination treatment with cetuximab and oxamate significantly enhanced 
inhibition of cell growth and survival compared with either single treatment alone, 
particularly in the cetuximab-resistant sublines. We found similar results by the 
combination treatment in other HNSCC cell lines, UMSCC1, OSC19, Sqcc/Y1, and 
TU167, which are naturally resistant to cetuximab-induced growth inhibition (Figure 22). 
Together, these data support a novel strategy of co-targeting LDH-A to improve the 
therapeutic effect of cetuximab in cancer cells. 
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Figure 21. Combination of cetuximab and oxamate effectively inhibit cell 
proliferation in HNSCC cells. The indicated cells were left untreated or treated 
with 20 nM cetuximab, 5 mM oxamate, or both for 5 days. Cell growth responses 
to cetuximab were measured by an MTT assay. The cell growth and survival in 
treated groups were expressed as a percentage of the optical density value in the 
corresponding untreated cells. 
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Figure 22. Combination of cetuximab and oxamate effectively inhibit cell 
proliferation in cetuximab-resistant HNSCC cells. The indicated cells were 
left untreated or treated with 20 nM cetuximab, 5 mM oxamate, or both for 5 
days. Cell growth responses to cetuximab were measured by an MTT assay. The 
cell growth and survival in treated groups were expressed as a percentage of the 
optical density value in the corresponding untreated cells. 
  
67 
 
4.2.9 Cetuximab has no significant effect on inhibiting glycolysis in nontransformed 
cells in normoxia 
        Most nontransformed cells consume much less glucose compared with cancer cells 
because normal cells use a more energy-efficient pathway, oxidative phosphorylation, 
for energy production. To determine whether the effect of cetuximab in inhibiting 
glycolysis is cancer cell selective, we examined the changes in cell proliferation, glucose 
consumption, lactate production, LDH-A activity and ATP level in NOM9-TK cells, an 
immortalized human head and neck epithelial cell line, with and without cetuximab 
treatment in normoxic culture.  Proliferation of NOM9-TK cells in the absence of EGF 
was slow and was barely inhibited by cetuximab (Figure 23A). NOM9-TK cells express 
a very low level of HIF-1α in culture under normoxia compared to hypoxia. Cetuximab 
treatment did not decrease LDH-A protein level in NOM9-TK cells (Figure 23B) and did 
not significantly inhibit glucose consumption (Figure 23C), lactate production (Figure 
23D), LDH-A activity (Figure 23E), or intracellular ATP level (Figure 23F) in the cells 
in normoxic culture. The absolute amount of lactate production was markedly less in 
NOM9-TK cells (Figure 23D) than in HN5 and FaDu cells for the same period (Figure 
16B). These findings indicate that cetuximab may inhibit aerobic glycolysis selectively 
in cancer cells through downregulation of LDH-A, which causes cancer cells that rely 
heavily on aerobic glycolysis for biosynthetic metabolism and energy production, to 
arrest at G1 phase. 
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Figure 23. Cetuximab does not affect glycolysis in normal cells. (A) NOM9-
TK cells were left untreated or treated with 20 nM cetuximab for 5 days in 
chemically-defined KGM medium supplemented with components provided in 
the SingleQuots kit except EGF. Cell growth response to cetuximab was 
measured by an MTT assay. (B) NOM9-TK cells were left untreated or treated 
with 20 nM cetuximab for 24 hours under normoxia. Cells treated the same way 
under hypoxia served as controls. Cell lysates were subjected to Western blot 
analysis with the indicated antibodies. (C) and (D) NOM9-TK cells were seeded 
into 6-well plates with 3 mL of low-glucose (1 g/L) cell culture medium and 
treated with or without 20 nM cetuximab for the indicated times. At each time 
point after treatment, the level of glucose remaining in the conditioned medium 
(C) and the level of lactate produced in the conditioned medium (D) were 
determined with assays described in materials and methods. (E) NOM9-TK cells 
were left untreated or treated with 20 nM cetuximab for the indicated time 
periods. Cells were harvested and homogenized, and samples containing equal 
amounts of proteins were subjected to an LDH-A activity assay as described in 
materials and methods. (F) NOM9-TK cells were left untreated or treated with 20 
nM cetuximab in serum-free keratinocyte growth medium for 4 hours. Cell 
pellets were harvested, and the intracellular level of ATP was measured with a 
luciferase-based ATP determination assay as described in materials and methods. 
The data presented are mean ± SD. 
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4.3 Discussion 
        Previously our lab has reported that cetuximab downregulates HIF-1, one of the key 
players in regulating tumor metabolism. Thus far, how cetuximab affects cancer cells in 
the perspective of metabolism is not clear. Here we reported that (1) Cetuximab inhibits 
glycolysis in cancer cells, but not in normal cells; (2) Overexpression of HIF-1 could 
abolish the role of cetuximab in mediating glycolysis inhibition in cancer cells; (3) 
Cetuximab mediated glycolysis inhibition is associated with the role of cetuximab in cell 
cycle arrest; (4) Combination of cetuximab and glycolysis inhibitor resensitizes 
responses to cetuximab in cetuximab-resistant cell lines. Our study, for the first time in 
literature, expands understanding of cetuximab-mediated EGFR targeted therapy to the 
field of cancer metabolism.  
        Cancer cells rely on an uninterrupted supply of energy and building blocks for 
fueling unlimited cell proliferation. An adequate supply of energy and biomass depends 
in large part on elevated glycolytic flux in cancer cells. On the other hand, the high 
reliance of cancer cells on glycolysis for energy and building blocks also made 
glycolysis, the “sweet tooth” of cancer, an appealing target for cancer therapeutics. 
Inhibition of glycolysis in cancer cells by cetuximab decreases the supply of energy and 
biomass needed for proliferation, and the cells are therefore arrested at G1 phase. 
Depending on the extent to which glucose-derived pyruvate is redirected to the 
tricarboxylic acid cycle for oxidative phosphorylation induced by glycolysis inhibition, 
inhibition of LDH-A may also induce apoptosis in addition to cell cycle arrest. This is 
because excess oxidative phosphorylation of pyruvate may cause overproduction of 
reactive oxygen species that are cytotoxic to cells, leading to apoptosis. Indeed, we 
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found evidence of apoptosis when cells were treated with cetuximab in combination with 
LDH-A knockdown by siRNA. 
        The most important characteristics of a cancer therapeutic drug is the highly 
selectivity to cancer cells and low cytotoxicity to normal cells. Here we reported that 
cetuximab selectively inhibits glycolysis only in tumor cells, but not in normal NOM9-
TK cells. This selectivity is based on the different glucose metabolic pattern of cancer 
cells and normal cells. Cancer cells and normal cells share the biochemical process of 
glycolysis from glucose to pyruvate. However, in the presence of oxygen, normal cells 
prefer to use pyruvate in mitochondria for tricarboxlic acid cycle and following 
oxidative phosphorylation to produce large amount of ATP; while cancer cells prefer to 
use pyruvate for aerobic glycolysis to produce intermediate metabolites as building 
blocks for anabolism, with an end-product of lactate. We found that cetuximab 
selectively inhibits the expression level and activity of LDHA, but not the other key 
glycolytic enzymes which catalyze conversion from glucose to pyruvate. In addition, we 
also found that cetuximab has only mild effects on the function of mitochondria. Both of 
them prove that in the perspective of metabolism, the effect of cetuximab is highly 
selective to cancer cells.  
        Another interesting finding of the current work is that HNSCC cells with resistance 
to cetuximab acquired through long-term adaptation or through experimental 
overexpression of HIF-1α-∆ODD remained at least partially sensitive to cetuximab-
induced inhibition of major cell signaling pathways downstream of EGFR, in contrast to 
resistance to cetuximab-induced decrease in the level of LDH-A. This finding indicates 
LDH-A as a potential better biomarker than the downstream signaling molecules for 
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predicting cancer cell responsiveness to cetuximab treatment. It is noteworthy that 
despite the elevation of HIF-1α or HIF-1α-∆ODD in the cetuximab-resistant sublines of 
HN5 (HN5-R and HN5-HIF-1α/∆ODD) and FaDu (FaDu-R and FaDu-HIF-1α/∆ODD), 
the basal level of LDH-A was only modestly elevated in these cells. This is most likely 
because the basal level of LDH-A was sufficient to drive the direction of glycolysis 
towards lactate production in these cells. It was when the cells were treated with 
cetuximab, the elevated HIF-1α or HIF-1α-∆ODD protected against downregulation of 
LDH-A by cetuximab. 
        The phenomenon that cetuximab could still inhibit EGFR-downstream signaling 
pathway activities in cetuximab-resistant cell lines also provides a novel strategy in 
overcoming cetuximab-resistance by targeting both EGFR-signaling pathways and 
tumor glycolysis in cetuximab-resistant cancer cells. Although targeting EGFR broadly 
inhibits its downstream signaling networks activated by the receptor tyrosine kinase, 
some of its downstream signaling pathways can be bypassed due to alternative and/or 
constitutive activation of these pathways at various levels, which causes the failure of 
EGFR-targeted therapy. Glycolysis is important for cancer progression by providing 
bioenergy and building blocks for cell growth. Here our data showed that combination of 
cetuximab and glycolysis inhibitor oxamate has synergetic effect in inhibiting cell 
growth in cetuximab-resistant cell lines.  
        An important caveat is that glycolysis inhibition by cetuximab may not be mediated 
only through inhibition of LDH-A. Inhibition of other glycolytic enzymes, which are 
subjected to regulation by HIF-1, might also be important for cetuximab to successfully 
inhibit cancer cell proliferation. Therefore, in contrast to overexpression of HIF-1α, 
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overexpression of LDH-A alone may not be sufficient to confer resistance to cetuximab. 
        In summary, we demonstrated that cetuximab inhibits cancer cell proliferation via 
inhibiting glycolysis. Our findings suggest that LDH-A may be a novel predictor of 
cetuximab response and also a target for sensitizing cetuximab-resistant cells to 
cetuximab treatment. Our work fills in a major gap in knowledge regarding the link 
between EGFR-targeted therapy and cancer cell metabolism, which could lead to a 
major advance in our understanding of how cetuximab inhibits the proliferation of 
cancer cells and development of new strategies for enhancing cetuximab-mediated anti-
EGFR therapy.  
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Chapter 5 Cetuximab downregulates EGFR-associated ASCT2 and decreases 
antioxidant capacity of HNSCC 
 
5.1 Introduction 
        The majority of HNSCCs express a high level of EGFR, however, only a small 
fraction of head and neck cancer patients respond to EGFR antibody cetuximab [119, 
120]. A consensus is emerging that many tumors are resistant to cetuximab because of 
frequent constitutive activation of oncogenes and/or mutational inactivation of tumor 
suppressor genes in EGFR downstream signaling pathways or redundant activation of 
EGFR downstream pathways by receptor tyrosine kinase other than EGFR [94, 121]. In 
vitro studies showed that even in cetuximab-sensitive cancer cell lines, cetuximab 
majorly induces cytostatic, rather than cytotoxic effect, through arresting cell cycle in 
G1 phase, accompanied by a decrease in cyclin-dependent kinase 2 activity, and an 
increase in the expression of cyclin-dependent kinase inhibitor p27KIP1 [122, 123]. Our 
novel findings in Chapter 4 elucidated that cetuximab-mediated glycolysis inhibition is 
the underlying mechanism of antitumor effect of cetuximab in the perspective of 
metabolism, further supporting that the effect of cetuximab is mainly through cell 
growth inhibition.  
         Different from normal cells, cancer cells prefer to convert glucose-generated 
pyruvate into lactate, even in the presence of oxygen, a phenomenon called “Warburg 
effect”. One of the major advantages for cancer cell to adopt the low-efficient energy 
yielding glycolytic pathway is the reduction of reactive oxygen species (ROS) 
production [124]. Mitochondria are the principle source of metabolically produced ROS 
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[125]. The flux of electrons carried by NADH and FADH2 through electron transport 
chain (ETC) leads to the formation of ROS in complex I, II, and III, where electrons can 
be prematurely reduce oxygen [126, 127]. Low levels of mitochondrial ROS production 
are required for cellular processes such as proliferation and differentiation; however, 
overproduction of ROS will lead to the initiation of senescence and apoptosis, or even 
non-signaling, irreversible damage to cellular components [69].  
        Evidence from recent studies showed that cancer cells, compared with normal cells, 
exhibit increased intrinsic ROS stress, because of oncogenic stimulation, increased 
metabolic activity, and mitochondrial malfunction [128-131]. Although increased 
amounts of ROS in cancer cells might stimulate cellular proliferation, promote mutations 
and genetic instabilities, and cause drug resistance, it can also be toxic to cancer cells, 
since cancer cells with increased oxidative stress are more vulnerable to damage by 
further ROS insults [132]. Therefore, it is rational to induce ROS overproduction by 
redox modulation to selectively kill cancer cells without causing significant toxicity to 
normal cells [133].  
        The fate of glucose metabolism, which either ends with glycolysis in cytoplasm or 
continues with tricarboxylic acid cycle (TCA cycle) for fully oxidation, is controlled by 
gate-keeping mitochondrial enzyme pyruvate dehydrogenase (PDH). PDH converts 
pyruvate to acetyl-CoA, which is fed to the TCA cycle, leading to the production of the 
electron donors NADH and FADH2 for further oxidative phosphorylation. PDH is 
phosphorylated and negatively regulated by PDH kinase (PDK). Targeting PDK in 
cancer cells may redirect the glycolysis product pyruvate to mitochondria for oxidative 
phosphorylation, which may lead to overproduction of ROS. However, our preliminary 
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studies showed that targeting PDK alone, either by siRNA or small molecule inhibitor 
dicholoroacetate, could not induce overproduction of ROS and apoptosis, because cancer 
cells, through unknown mechanisms, maintain a homeostatic balance between the 
formation of ROS and their removal by endogenous antioxidant defense mechanism in 
response to PDK inhibition. In this chapter, we hypothesized that cetuximab decreases 
intracellular GSH level, causing inadequate antioxidant defensive capacity in cancer 
cells. We tested the cytotoxic effect induced by combination of cetuximab and PDK1 
targeting in a couple of cetuximab-sensitive and cetuximab-resistant HNSCC models, in 
vitro and in vivo. We elucidated the contribution of cetuximab in the novel combination 
strategy by finding an EGFR associated membrane protein ASCT2, which regulates 
glutamine uptake and following GSH synthesis. Findings in this chapter discover a novel 
mechanism of cetuximab in regulating anti-oxidant capacity in cancer cells, and provide 
a novel and efficient therapeutic strategy for improving the response of cancer patients to 
cetuximab, which is synergetic and synthetic lethal and is independent of EGFR kinase 
inhibition.  
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5.2 Results 
5.2.1 Combination of cetuximab and silencing PDK1, but not either treatment alone, 
induces apoptosis.  
        Inhibition of PDK1, through activation of PDH, redirects the glucose-derived 
pyruvate for oxidative phosphorylation through the tricarboxylic acid cycle, and 
generates ROS as a by-product. We firstly hypothesized that inhibition of PDK1 may 
result in apoptosis through overproduction of ROS in cancer cells. However, we found 
that in HN5 and FaDu cells, silencing PDK1 with any 3 of different siRNAs for 72 hours 
only resulted in a slight inhibition of cell proliferation through MTT assay (Figure 24A). 
The growth inhibition induced by PDK1 siRNA is similar to that induced by cetuximab 
treatment for 24 hours. Silencing PDK1 failed to increase cleavage of PARP and 
Caspase 3, indicators of apoptosis, and to decrease clonogenic capacity in HN5 and 
FaDu cells (Figure 24B and C), indicating that the inhibitory effect induced by PDK1 
siRNA is mainly cytostatic rather than cytotoxic effect.  Consistent with our result in 
4.2.7, cetuximab treatment alone for 24 hours did not readily induce apoptosis or 
decrease clonogenic capacity in HN5 and FaDu cells either. Interestingly, we found that 
combination of cetuximab and PDK1 siRNA significantly lowered cell viability 
compared with the viability with either treatment alone (Figure 24A), induced cleavage 
of PARP and Caspase 3 (Figure 24B), and markedly reduced the number of surviving 
clones (Figure 24C). These data showed that different from either treatment alone, 
combination of cetuximab and PDK1 siRNA are toxic to HNSCC cells.  
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Figure 24. Impact of cetuximab and PDK1 silencing, alone or in 
combination, on cell proliferation, apoptosis, and clonogenic capacity. (A) 
HN5 and FaDu cells were subjected to PDK1 silencing with each of 3 different 
PDK1 siRNAs or control siRNA for 72 hours. During the last 24 hours, cells 
were then treated with or without 20 nM cetuximab, and then MTT assays were 
performed for determination of the responses of the cells to the treatment. (B) 
HN5 and FaDu cells treated as in (A) were harvested. Cell lysates were prepared, 
and equal amounts of cell lysates were subjected to Western blot analysis with 
the indicated antibodies. (C) HN5 and FaDu cells treated as in (A) were seeded at 
low density and subjected to a clonogenic survival assay as described in 
materials and methods. 
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5.2.2 Combination of cetuximab and silencing PDK1 induces overproduction of 
ROS and loss of mitochondrial membrane potential 
        Both cetuximab and PDK1 inhibition could reverse Warburg effect and redirect 
glucose metabolism from aerobic glycolysis to oxidative phosphorylation, which will 
generate ROS. To elucidate the mechanism through which combination of cetuximab 
and PDK1 siRNA are toxic to cancer cell, we examined the effect of cetuximab and 
PDK1 siRNA, alone or in combination, in inducing ROS production. Figure 25A 
showed that either cetuximab or PDK1 silencing alone did not result in detectable ROS, 
while combination of them led to overproduction of ROS in both HN5 and FaDu cells. 
Similar phenomenon was confirmed in an independent ROS detection assay with flow 
cytometry (Figure 25B).  
        Mitochondrial membrane potential, ∆ψm, is an important parameter of 
mitochondrial function used as an indicator of cell health [134]. Overproduction of ROS 
will cause dysfunction of complex I of electron transport chain, limit the efflux of H+, 
and lead to the decrease of ∆ψm. Upon sustained and significant decrease in ∆ψm, the 
voltage-sensitive mitochondrial transition pore opens, allowing the efflux of many 
proapoptotic factors and the initiation of apoptosis. To directly link the ROS 
overproduction and apoptosis induced by combination of cetuximab and PDK1 siRNA, 
we measured ∆ψm in HN5 and FaDu cells with treatment of cetuximab and PDK1 
siRNA, alone or in combination by the staining of ∆ψm-dependent fluorescent dye 
tetramethyl rhodamine methyl ester (TMRM). Consistence with the finding in ROS 
production, either treatment alone did not induce loss of ∆ψm, while combination 
treatment caused a significant decrease of ∆ψm (Figure 25C and D).  
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Figure 25. Combination of cetuximab and PDK1 siRNA induces ROS 
overproduction and loss of ∆ψm. (A) and (B) HN5 and FaDu cells treated as 
indicated for 24 hours were stained with ROS-sensitive fluorescent dye provided 
in Enzo’s ROS detection kit for 1 hour. In (A), cells were screened under 
fluorescent microscope and representative area of ROS-stained cells and their 
phase contrast pictures are shown. In (B), cells were subjected to flow cytometry 
analysis. (C) and (D) HN5 and FaDu cells treated as indicated for 24 hours were 
stained with ∆ψm-sensitive fluorescent dye TMRM and counterstained with 
Hoechst for nuclei. In (C), cells were screened under fluorescent microscope and 
representative areas of TMRM- and Hoechst-stained cells and their overlay are 
shown. In (D), relative TMRM was determined by ratio of the reading at 590 nm 
(TMRM) over 460 nm (Hoechst) wavelength with a fluorescence plate reader 
and expressed as a percentage of the value of control group.    
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5.2.3 Combination of cetuximab and PDK1 inhibitor DCA induces overproduction 
of ROS, loss of ∆ψm, and apoptosis, all of which could be rescued by addition of 
antioxidant N-acetyl-cysteine 
        To confirm the effect of PDK1 targeting, we employed a PDK1 specific inhibitor, 
dicholoroacetate (DCA), to mimic PDK1 siRNA. HN5 and FaDu cells were treated with 
cetuximab and 10 mM DCA for 24 hours, alone or in combination, and cellular ROS, 
mitochondrial membrane potential, and apoptosis were detected. Similar to PDK1 
siRNA, DCA alone did not induce detectable ROS production (Figure 26A and B) or 
loss of ∆ψm (Figure 26C and D). DCA also failed to induce apoptosis (Figure 26E and 
F). Cetuximab plus DCA significantly caused overproduction of ROS and loss of ∆ψm, 
and led to apoptosis, as indicated by PARP and Caspase 3 cleavage, and an independent 
DNA fragmentation assay.  
        Addition of N-acetyl-cysteine (NAC), a precursor of antioxidant GSH, almost 
totally depleted overproduction of ROS (Figure 26A and B) and rescued loss of ∆ψm 
(Figure 26C and D) induced by combination of cetuximab and DCA. In HN5 cells, 
addition of NAC or membrane permeable GSH in cell culture medium largely rescued 
the cytotoxic effect induced by cetuximab plus DCA (Figure 26G and H). All of these 
data above indicated that the cytotoxic effect induced by cetuximab and PDK1 targeting 
is through ROS overproduction.  
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Figure 26. Combination of cetuximab and DCA induces overproduction of 
ROS, loss of ∆ψm, and apoptosis. (A) and (B) HN5 and FaDu cells treated as 
indicated for 24 hours were stained with ROS-sensitive fluorescent dye provided 
in Enzo’s ROS detection kit for 1 hour. In (A), cells were screened under 
fluorescent microscope and representative area of ROS-stained cells and their 
phase contrast pictures are shown. In (B), cells were subjected to flow cytometry 
analysis. (C) and (D) HN5 and FaDu cells treated as indicated for 24 hours were 
stained with ∆ψm-sensitive fluorescent dye TMRM and counterstained with 
Hoechst for nuclei. In (C), cells were screened under fluorescent microscope and 
representative areas of TMRM- and Hoechst-stained cells and their overlay are 
shown. In (D), relative TMRM was determined by ratio of the reading at 590 nm 
(TMRM) over 460 nm (Hoechst) wavelength with a fluorescence plate reader 
and expressed as a parentage of the value of control group. (E) and (F) HN5 and 
FaDu cells were treated with cetuximab (20 nM) and DCA (10 mM), alone or in 
combination for 24 hours. Cell lysates were prepared for Western blot with 
indicated antibodies in (E) and for detection of apoptosis by ELISA using a kit 
from Roche in (F). (G) and (H) HN5 cells were treated with cetuximab (20 nM) 
and DCA (10 mM) for 24 hours, alone or in combination in the presence or 
absence of GSH-ester (2 mM) or NAC (4 mM).  Cell lysates were prepared for 
Western blot with indicated antibodies in (G) and for detection of apoptosis by 
ELISA in (H). 
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5.2.4 Combination of cetuximab and PDK1 targeting induces apoptosis in 
cetuximab-resistant cells 
        Most patients treated with cetuximab develop acquired resistance, even they 
respond to cetuximab treatment in the beginning. To examine whether co-targeting 
PDK1 re-sensitizes responses of cancer cells to cetuximab treatment in cetuximab 
resistant cells, we used cetuximab-acquired resistant sublines HN5-R and FaDu-R, 
generated from HN5 and FaDu by subjecting to cetuximab with stepwise increases in 
concentration as described in 4.2.1. HN5-R and FaDu-R were treated with each of 3 
pairs of PDK1 siRNAs and cetuximab, alone or in combination. We found that 
cetuximab could still induce apoptosis (Figure 27A and B) and decrease clonogenic 
capacity (Figure 27C) in HN5-R and FaDu-R cells. These results indicated that the 
contribution of cetuximab in this novel combination might be different from its role in 
EGFR-downstream cell signaling inhibition, failure of which is the major mechanism 
underlying cetuximab resistance. In addition, silencing PDK1 alone showed cytotoxic 
effect to some extent in HN5-R and FaDu-R cells, which is a different phenomenon in 
HN5 and FaDu cells. This is because the resistant sublines are more relied on glycolysis 
compared to their counterparts (Figure 14), and redirection of glucose metabolism away 
from glycolysis induced by PDK1 silencing will be more toxic to the resistant sublines.  
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Figure 27. Combination of cetuximab and PDK1 siRNA are cytotoxic in 
cetuximab-resistant cancer cells. (A) and (B) HN5-R and FaDu-R cells were 
subjected to PDK1 silencing with each of 3 different PDK1 siRNAs or control 
siRNA for 72 hours. During the last 24 hours, cells were then treated with or 
without 20 nM cetuximab. Cells were harvested and cell lysates were prepared 
for Western blot with indicated antibodies in (A) and for detection of apoptosis 
by ELISA using a kit from Roche in (B). (C) HN5-R and FaDu-R cells were 
seeded at low density, treated as in (A) and (B) and subjected to a clonogenic 
survival assay as described in materials and methods. 
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5.2.5 Combination of cetuximab and DCA inhibits growth of HNSCC xenografts 
        To determine whether combination of cetuximab and PDK1 targeting would have 
better therapeutic effect compared with either drug alone in vivo, we used 
bioluminescent sublines of paired FaDu and FaDu-R that not only can grow in nude 
mice but also can be tracked using an in vivo imaging system (IVIS) to monitor tumor 
growth. A bioluminescent subline of natural occurred cetuximab-resistant cell line 
UMSCC1 and paired HN5 and HN5-R cell lines, all of which can form tumors in nude 
mice, were also employed in the in vivo experiments. Different cells were inoculated 
subcutaneously on the right flanks of nude mice. When tumors were well established at 
the volume of 150-250 mm3, the nude mice that had developed tumors were divided into 
six groups (6-7 mice in each group) with similar average tumor volume, and treated with 
vehicle, cetuximab (0.25 mg/mouse, bi-weekly), DCA (50 mg/kg/day or 250 mg/kg/day, 
daily), or combination of cetuximab and DCA for 21 days. Tumor volume was measured 
twice a week with a digital caliper. For bioluminescent sublines, tumors were also 
screened under IVIS system at day 21 from treatment start date. After the end of 
treatment, measurement of tumor volume was continued in each group until the group 
had less than 4 mice.           
        Xenograft of FaDu cells showed some responses to the treatment of cetuximab or 
DCA alone during treatment time, and much better response to the combination (Figure 
28A and B). Interestingly, when the treatment was stopped, in the groups treated with 
either cetuximab or DCA alone, FaDu xenograft tumors grew back very quickly; while 
in the groups treated with cetuximab plus DCA, the xenograft tumors were examined for 
5 months and did not grow back. Xenograft of FaDu-R cells exhibited considerable 
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resistance to cetuximab treatment alone. Combination of cetuximab and DCA produced 
substantially better therapeutic effects than either treatment alone, and xenograft tumors 
treated with combination did not grow back in 5 months. Since xenograft of HN5 cells 
has a very good response to cetuximab mono-treatment (Figure 28C), we did not 
combine the treatment with DCA. In xenograft of HN5-R cells, we also observed that 
combination of cetuximab and DCA had a significant better effect in inhibiting tumor 
growth; and compare with either treatment alone, combination treatment totally 
abolished the capacity of xenograft tumors to grow, even the treatment was stopped, 
suggesting that tumor cells were killed rather than static.  Similar therapeutic effect was 
also confirmed in the xenograft of natural occurred cetuximab-resistant cell line 
UMSCC1 (Figure 28D and E). All these data indicated that cetuximab or DCA treatment 
alone may have cytostatic effect in vivo, depending on different xenograft of cells; 
however, they have little or no cytotoxic effect. Xenograft tumors treated with either 
drug alone grew back as soon as the treatments were stopped. Combination of cetuximab 
and DCA efficiently inhibited xenograft tumors, not only in cetuximab-sensitive models, 
but also in cetuximab-resistant models. More importantly, xenograft tumors with 
combination treatment did not recur after treatment stopped, indicating that tumor cells 
were killed.  
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Figure 28. Combination of cetuximab and DCA inhibits tumor growth in 
vivo. Bioluminescent sublines of FaDu and FaDu-R, parental HN5 and HN5-R, 
and bioluminescent sublines of UMSCC1 were inoculated subcutaneously into 
the right flanks of nude mice. When tumors were well established at the volume 
of 150-250 mm3, the nude mice of each kind of xenograft tumors that had 
developed were divided into six groups (6-7 mice in each group) with similar 
average tumor volume, and treated with vehicle, cetuximab (0.25 mg/mouse, bi-
weekly), DCA (50 mg/kg/day or 250 mg/kg/day, daily), or combination of 
cetuximab and DCA for 21 days. In (A), (C) and (D), tumor volume was 
measured twice a week with calipers and was plotted as a function of the days. 
After the end of treatment, measurement of tumor volume was continued. Mice 
in any groups were sacrificed when the tumor burdens were too big or when the 
mice became morbid or moribund. When the remaining numbers of mice in any 
groups became less than 4, the entire group was terminated. In (B) and (E), 
xenograft tumor of bioluminescent sublines of FaDu, FaDu-R and UMSCC1 
were screened under IVIS system at day 21 from treatment start date.  
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5.2.6 Induction of apoptosis by cetuximab plus PDK1 silencing or DCA is not 
dependent on inhibition of EGFR kinase activity by cetuximab 
        The major cetuximab-resistant mechanism is the constitutively activation of EGFR-
downstream cell signals induced by activation of oncogenes or loss-of-function mutation 
of tumor suppressor genes.  Since combination of cetuximab and PDK1 targeting by 
siRNA or DCA induced apoptosis in vitro and in vivo, even in cetuximab-resistant cell 
lines, we hypothesized that the contribution of cetuximab in this novel combination 
treatment is independent on its function in inhibiting EGFR kinase activity. To test this 
hypothesis, we determined whether treatment with the small molecule EGFR kinase 
inhibitor gefitinib plus PDK1 silencing or DCA would result in similar effects to those 
achieved with cetuximab plus PDK1 silencing or DCA with respect to apoptosis. Unlike 
cetuximab, gefitinib, which successfully inhibited EGFR kinase activity as shown by 
reduced autophosphorylation of EGFR on Y1068,  did not have the synergetic effect on 
inducing cleavage of PARP and Caspase 3, and apoptosis (Figure 29A). Combination of 
gefitinib and DCA did not have synergetic effect on inducing apoptosis either, despite of 
strong EGFR kinase activity inhibition by gefitinib (Figure 29B).  
        To further confirm the combination effect of cetuximab and PDK1 targeting is 
independent of the role of cetuximab in EGFR kinase activity inhibition, we transfected 
HN5 with a constitutively active H-Ras mutant (H-Ras G12V), as described in 3.2.4. H-
Ras mutation is one of the major cetuximab-resistant mechanisms in HNSCC. 
Constitutively activation of Ras abolishes the anti-proliferation effect of cetuximab 
through activating EGFR-downstream signals. Interestingly, although overexpression of 
RasG12V conferred resistance to cetuximab-induced inhibition of EGFR-downstream 
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signaling, as shown by the unchanged level of phosphorylation of Akt at S473 and 
phosphorylation of p70S6k at S371 after cetuximab treatment, it did not protect cells 
from induction of apoptosis by the combination of cetuximab and PDK1 siRNA (Figure 
29C). Together, these data not only support that cetuximab plus PDK1 targeting induces 
apoptosis independently of inhibition of EGFR kinase activity by cetuximab, but also 
provide a potential novel therapeutic strategy to bypass most current known cetuximab 
resistant mechanism.   
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Figure 29. Induction of apoptosis by combination of cetuximab and PDK1 
targeting is independent of EGFR kinase inhibition by cetuximab. (A) HN5 
cells were subjected to PDK1 siRNA or control siRNA for 72 hours. During the 
last 24 hours, cells were then treated with cetuximab (20 nM), gefitinib (0.2 µM), 
or neither as indicated. (B) HN5 cells were treated with cetuximab (20 nM) or 
gefitinib (0.2 µM) alone or in combination with DCA (10 mM) for 24 hours. (C) 
HN5 cells transfected with RasG12V were subjected to knockdown of PDK1 
with each of different PDK1 siRNAs or control siRNA for 72 hours. During the 
last 24 hours, these cells and parental HN5 cells were treated with cetuximab or 
not. In (A), (B), and (C), cells were harvested after treatment. Cell lysates were 
prepared for Western blot analysis with antibodies shown and for detection of 
apoptosis by ELISA.  
  
101 
 
5.2.7 Induction of cetuximab plus DCA requires both expression of EGFR on the 
cell surface and effective internalization of EGFR by cetuximab 
        To elucidate the role of EGFR in induction of apoptosis by combination of 
cetuximab and DCA, we next tested whether EGFR silencing plus DCA produced 
effects similar to those of cetuximab plus DCA and whether expression of EGFR on the 
cell surface is still required for the combination treatment-induced apoptosis. Figure 30A 
showed that compared with cetuximab plus DCA which induced PARP cleavage, 
knockdown of EGFR by each of 3 different EGFR siRNAs plus DCA did not induce 
PARP cleavage in FaDu cells. This finding was further confirmed in HN5 cells (Figure 
30B). Moreover, knockdown of EGFR decreased the level of apoptosis induced by the 
combination of cetuximab and DCA, indicating that EGFR expression was required for 
induction of apoptosis by this combination treatment.   
        The anti-proliferation effect of cetuximab is not only through inhibition of EGFR 
kinase activity, but also through induction of EGFR internalization and degradation by 
its bivalent binding to EGFR. We thus hypothesized that cetuximab contributes to the 
combination of cetuximab and PDK1 targeting in perspective of EGFR internalization 
and degradation. We tested whether silencing selected members of the Rab G proteins, 
which are involved in EGFR endocytosis, had any effect on induction of apoptosis by 
the combination treatment. Figure 30C showed that knockdown of Rab5, which involved 
in early endosomes, inhibited cleavage of PARP induced by the combination treatment, 
whereas knockdown of Rab11, which involved in recycling endosomes, did not have 
similar effect. Taken together, these observations indicated that cetuximab-induced 
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EGFR internalization, which is EGFR kinase inhibition independent, plays a critical role 
in induction of apoptosis by cetuximab plus PDK1 targeting.   
 
Figure 30. Induction of apoptosis by combination of cetuximab and DCA 
required both expression of EGFR on the cell surface and effective 
internalization of EGFR by cetuximab. (A) FaDu cells were subjected to 
knockdown of EGFR with each of 3 pairs of different EGFR siRNAs or control 
siRNA for 72 hours. During the last 24 hours, cells were treated with cetuximab 
(20 nM) or DCA (10 mM), alone or in combination in control siRNA-treated 
cells and with DCA only in EGFR-siRNA treated cells. (B) HN5 cells were 
exposed to control siRNA or each of 2 pairs of different EGFR siRNAs for 72 
hours. During the last 24 hours, cells were treated with cetuximab (20 nM) or 
DCA (10 mM), alone or in combination in both control siRNA and EGFR siRNA 
treated cells. (C) HN5 and FaDu cells were exposed to Rab5 and Rab11 siRNA 
or control siRNA for 72 hours. Cells were then treated as in (B). After treatments, 
cell lysates were prepared for Western blot analysis with indicated antibodies.  
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5.2.8 DCA upregulates glutamine transporter ASCT2 and increase glutamine 
uptake, which leads to resistance to DCA treatment 
        To elucidate the mechanism of cetuximab in contributing to the apoptosis induction 
by combination treatment with PDK1 targeting, we first need to figure out why targeting 
PDK1, a theoretical approach to produce ROS, failed to induce detectable ROS and 
apoptosis, as described in 5.2.2. We found that in both HN5 and FaDu cells, DCA 
treatment upregulated the protein expression of ASCT2, one of the most major 
glutamine transporters (Figure 31A), as well as glutamine uptake (Figure 31B), both of 
which could be rescued by addition of NAC.  
        Catalyzed by mitochondrial enzyme glutaminase, glutamine is converted to 
glutamate, which is one of the precursors for GSH synthesis. We hypothesized that 
upregulation of ASCT2 induced by DCA would increase glutamine uptake and GSH 
synthesis, leading to the upregulation of intracellular GSH levels. In HN5 cells, 
knockdown of ASCT2 with siRNA decreased glutamine uptake, and overexpression of 
ASCT2 increased glutamine uptake (Figure 31C), indicating a direct link between levels 
of ASCT2 protein and intracellular GSH.   
        To confirm ASCT2 upregulation induced by DCA is a mechanism conferring 
resistance to DCA, we knockdown ASCT2 with siRNA and treated HN5 and FaDu cells 
with DCA. Knockdown of ASCT2 significantly increased responses to DCA in HN5 and 
FaDu cells, as shown by induction of PARP cleavage (Figure 31D). All these 
observations indicated that DCA upregulates ASCT2 and promote glutamine uptake in a 
ROS-dependent manner, and upregulation of ASCT2 is a cellular protection mechanism 
against oxidative stress and leads to resistance to DCA treatment.    
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Figure 31. DCA upregulates ASCT2 and glutamine uptake, leading to 
resistance to DCA treatment. (A) FaDu and HN5 cells were treated with DCA 
for 24 hours with and without concurrent treatment of 10 mM NAC. After 
treatments, cell lysates were prepared for Western blot analysis with indicated 
antibodies. (B) FaDu and HN5 cells were treated as in (A), and 3H-glutamine 
uptake was determined afterwards as described in materials and methods. (C) 
HN5 cells were exposed to control siRNA or each of 2 pairs of different ASCT2 
siRNAs for 72 hours, or transfected with a vector containing ASCT2 or a control 
vector for 48 hours. 3H-glutamine uptake was determined afterwards as described 
in materials and methods. (D) FaDu and HN5 cells were subjected to knockdown 
of ASCT2 with each of 2 individual ASCT2 siRNA or control siRNA for 72 
hours. During the last 24 hours, cells were treated with 10 mM DCA with or 
without concurrent treatment of 10 mM NAC. Cell lysates were prepared for 
Western blot analysis with indicated antibodies.  
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5.2.9 ROS upregulates ASCT2, knockdown of which sensitizes responses to H2O2 
and other ROS inducers     
        To further confirm the role of ASCT2 upregulation in protecting cells from 
oxidative stress, HN5 and FaDu cells were treated with H2O2, then glutamine uptake and 
intracellular GSH levels were measured. Similar to the effect induced by DCA, H2O2 
upregulated glutamine uptake (Figure 32A) and intracellular GSH level (Figure 32B), 
both of which could be regulated by addition of NAC. Overexpression of ASCT2 largely 
rescued apoptosis induced by high dose of H2O2 (1 mM) (Figure 32C), and knockdown 
of ASCT2 by siRNA sensitized responses to low dose of H2O2 (0.1 mM) by inducing 
apoptosis (Figure 32D), showing the critical role of ASCT2 in protecting cells against 
oxidative stress.  
        Two other well-known ROS inducer, pyocyanin and phenethyl isothiocyanate 
(PEITC), were also used to test their effects on ASCT2 and PARP cleavage in HN5 and 
FaDu cells.  Pyocyanin induces ROS through inactivating catalase by reducing its gene 
transcription and directly targeting the enzyme itself, and PEITC induces ROS through 
affecting complexes within the mitochondrial electron transport chain [135]. Similar to 
the upregulation of ASCT2 induced by H2O2 (Figure 32D), pyocyanin and PEITC also 
upregulated ASCT2 in both HN5 and FaDu cells (Figure 32E and F). Low doses of 
pyocyanin (10 µM) and PEITC (5 µM) did not induce apoptosis, while knockdown of 
ASCT2 plus pyocyanin and PEITC significantly induced apoptosis, as shown by PARP 
cleavage. Taken together, these observations showed that cancer cells response to ROS 
by upregulating ASCT2, and subsequent increases of glutamine uptake and GSH 
synthesis, leading to protection from oxidative stress and resistance to ROS inducers.  
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Figure 32. ROS upregulates ASCT2 and knockdown of ASCT2 sensitizes 
responses to H2O2 and other ROS inducers. (A) FaDu and HN5 cells were 
treated with 1 mM H2O2 for 24 hours with and without concurrent treatment of 
10 mM NAC. 3H-glutamine uptake was determined afterwards as described in 
materials and methods.  (B) FaDu and HN5 cells were treated with 1 mM H2O2 
for 24 hours. Intracellular GSH level was measured using the Cayman GSH kit 
as described in materials and methods. (C) FaDu and HN5 cells transfected with 
control vector or ASCT2 construct were exposed to 1 mM H2O2 for 24 hours 
with or without concurrent treatment of 10 mM NAC. Cell lysates were prepared 
for Western blot analysis with indicated antibodies. (D), (E), and (F) FaDu and 
HN5 cells were subjected to knockdown of ASCT2 with each of 2 individual 
ASCT2 siRNA or control siRNA for 72 hours. During the last 24 hours, cells 
were treated with 0.1 mM H2O2 (D), 10 µM pyocyanin (E), or 5 µM PEITC (F) 
with or without concurrent treatment of 10 mM NAC. Cell lysates were prepared 
for Western blot analysis with indicated antibodies.  
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5.2.10 Cetuximab downregulates ASCT2, decreases glutamine uptake and GSH 
levels, sensitizing cancer cells to DCA induced oxidative stress   
        Upregulation of ASCT2 and subsequent increase of GSH is a major mechanism 
underlying the resistance to DCA and other ROS inducers. In HN5 cells, treatment with 
cetuximab significantly downregulated protein level of ASCT2 (Figure 33A), and 
decreased glutamine uptake (Figure 33B) and intracellular GSH level (Figure 33C), 
suggesting that cetuximab contributes to the combination treatment with DCA to induce 
ROS by scavenging intracellular GSH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33. Cetuximab downregulates ASCT2, decreases glutamine uptake 
and intracellular GSH levels. (A) HN5 cells were treated with cetuximab for 24, 
48, or 72 hours. Cell lysates were prepared for Western blot analysis with 
indicated antibodies. (B) HN5 cells were treated as in (A). 3H-glutamine uptake 
was determined afterwards as described in materials and methods. (C) HN5 cells 
were treated as in (A). Intracellular GSH level was measured using the Cayman 
GSH kit as described in materials and methods. 
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5.2.11 ASCT2 is associated with EGFR, both of which are co-internalized and 
degraded by induction of cetuximab  
        Cetuximab contributes to the combination treatment with targeting PDK1 to induce 
apoptosis mainly through downregulating ASCT2, and this role of cetuximab should be 
independent of EGFR kinase activity inhibition. So we hypothesized that cetuximab 
downregulates ASCT2 through EGFR-mediated internalization and degradation. 
Through immunoprecipitation, we found that in HN5 cells, ASCT2 and EGFR were 
associated with each other (Figure 34A). The association of ASCT2 and EGFR was 
confirmed by immunoprecipitation in multiple HNSCC cells, including FaDu, UMSCC1, 
UMSCC2, UMSCC22A, UMSCC22B, TU167, MDA1986, and HN30 (Figure 34B). In 
HN5 cells, treatment with cetuximab for 10 hours induced decreases in EGFR and 
ASCT2 protein levels in cell membranes, but significant increases in EGFR and ASCT2 
protein levels in cytoplasm (Figure 34C), showing the internalization of associated 
EGFR and ASCT2 induced by cetuximab.  
        To prove that cetuximab-mediated ASCT2 downregulation is caused by ASCT2 
internalization and degradation, HN5 cells were subjected to siRNA of Rab5, a critical 
factor for the formation of early endosome and membrane protein internalization (Figure 
34D and E). Knockdown of Rab5 abolished the role of cetuximab in downregulating 
ASCT2 and EGFR, as well as decreasing intracellular GSH levels, indicating the critical 
role of ASCT2 internalization in cetuximab-mediated ASCT2 downregulation and GSH 
scavenging.    
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Figure 34. ASCT2 is associated with EGFR, and the complex can be 
internalized and degraded by cetuximab. (A) HN5 cells were lysed and the 
lysates were incubated with the anti-EGFR monoclonal antibody cetuximab (4 
µg), rabbit anti-ASCT2 antibody (4 µg), or with nonspecific normal mouse 
immunoglobulin G (IgG) (4 µg), and then incubated with 20 µl protein A beads 
for 10 hours.  The immunoprecipitates were analyzed by Western blot for 
indicated antibodies. (B) Indicated HNSCC cells were lysed and the lysates were 
analyzed for association of EGFR and ASCT2 by immunoprecipitation as 
described in (A). (C) HN5 cells were treated with 20 nM cetuximab for 10 hours. 
The cells were then subjected to cell membrane and cytoplasmic fractionations 
for Western blotting with the indicated antibodies. (D) HN5 cells were subjected 
to knockdown of Rab5 for 72 hours. During the last 24 hours, cells were treated 
with or without 20 nM cetuximab. Cell lysates were prepared for Western blot 
analysis with indicated antibodies. (E) HN5 cells were treated as in (D) and 
intracellular GSH level was measured using the Cayman GSH kit as described in 
materials and methods. 
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5.3 Discussion 
        The major findings in this part are: (1) The combination of cetuximab and PDK1 
targeting induces overproduction of ROS and loss of mitochondrial membrane potential, 
leading to apoptosis; (2) The contribution of cetuximab in the above combination is 
independent of its function in EGFR kinase activity inhibition; (3) Cetuximab deceases 
intracellular GSH level through downregulating glutamine transporter ASCT2; (4) 
ASCT2 is associated with EGFR, and ASCT2-EGFR complex can be co-internalized 
and degraded mediated by cetuximab. These findings not only reveal a novel role of 
cetuximab in regulating cellular redox status, but also indicate an innovative therapeutic 
strategy to improve response to cetuximab, particularly in patients with EGFR-positive 
but cetuximab-resistant tumors.  
        A major mechanism underlying resistance to cetuximab is that cetuximab fails to 
inhibit EGFR downstream signaling cascade, because of oncogene gain-of-function 
mutation (such as H-Ras), tumor suppressor gene loss-of-function mutation (such as 
PTEN), and cross activation by activation of other growth factor receptors (such as IGF, 
c-MET). In this study, we reported that the novel combination effect by cetuximab and 
PDK1 targeting is independent of EGFR kinase activity inhibition induced by cetuximab. 
Thus, this novel combination strategy will reverse most currently known cetuximab 
resistance, if the tumors have expression of EGFR. In addition, since both cetuximab and 
PDK1 inhibitor DCA have been approved by FDA, findings in this part could be easily 
translated to clinical trials.  
        Most cancer cells depend on fast glucose consumption for their survival and 
continued growth, since the energy yielding efficiency is low for cancer cells which 
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adopt aerobic glycolysis as the major glucose metabolic pathway. Recently, it was 
reported that many cancer cells are also addicted to glutamine, although glutamine is 
considered to be a nonessential amino acid that can be synthesized within the cells [77, 
136]. ASCT2 is the major transporter of glutamine in cancer cells. Information from 
Cancer Genome Anatomy Project (http://cgap.nci.nih.gov) indicates that expression of 
ASCT2 is elevated in a wide spectrum of primary human cancers compared with 
adjacent normal tissues. Many cancer cell lines have shown sensitivity to glutamine 
starvation [137], suggesting glutamine metabolism an appealing target for cancer 
therapeutics. However, although some glutamine metabolic inhibitors showed a 
significant cytotoxic effect against certain tumor types both in culture and in mouse 
xenograft models in preclinical tests, they were discontinued because of dose-limiting 
neurotoxicity, gastrointestinal toxicity and myelosuppression [138]. Since normal tissues 
also need uptake of glutamine, directly targeting ASCT2 was also considered to be 
highly toxic. Here we found that ASCT2 are associated with EGFR, which is 
overexpressed in many types of cancer. Our current study indicates that cetuximab-
mediated EGFR internalization and degradation, which indirectly downregulates ASCT2, 
is an alternative and effective way to inhibit glutamine uptake and following GSH 
synthesis.  
        In addition, the high cancer cell selectivity of our new combination treatment is 
based on the major difference in metabolism between normal cells and cancer cells that 
lead them to respond differently to inhibition of PDK1. Normal cells use glucose more 
efficiently than cancer cells through oxidative phosphorylation in mitochondria. In 
normal cells, ROS are usually not overproduced. In contrast, cancer cells consume a lot 
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of glucose via aerobic glycolysis that is preferentially directed toward lactate production. 
Inhibition of PDK1 forcibly switches cancer metabolism from aerobic glycolysis to 
oxidative phosphorylation that will cause overproduction of ROS, leading to oxidative 
stress. Since cancer cells with increased oxidative stress are more vulnerable to damage 
by further ROS insults, induction of ROS overproduction will be more cytotoxic to 
cancer cells compared with normal cells.  
        It is rational to induce overproduction of ROS to selectively induce apoptosis in 
cancer cells, however, cancer cells respond to increased oxidative stress by increasing 
the anti-oxidant capacity. Here we found that ASCT2 is upregulated by oxidative stress, 
leading to the increase of glutamine uptake and intracellular GSH levels. The mechanism 
underlying the upregulation of ASCT2 by ROS is unknown. Whether upregulation of 
ASCT2 is a transcriptional or posttranslational effect need to be understood. Elucidation 
of the molecular players for upregulation of ASCT2 by ROS will provide another target 
to increase responses to therapeutic strategies by inducing oxidative stress.  
        An important caveat is that the synthesis of GSH might not only be regulated by 
uptake of glutamine. ASCT2 regulates the transport of glutamine, cysteine, and a few 
other neutral amino acids into cells. Because of the oxidizing environment in the 
extracellular space, most cysteine is oxidized into the dimeric cystine. Cells therefore 
mainly use the stable cystine as a precursor for GSH synthesis, and cystine is exclusively 
transported by the Xc(-) cystine/glutamate antiporter, which include xCT, the regulatory 
subunit of the system, and 4F2hc/CD98, the functional subunit of the system. Once 
inside the cell, cystine is rapidly reduced to cysteine because of the reducing intracellular 
milieu. Cysteine was considered to be the rate-limit part for GSH synthesis. Glutamate, 
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which is converted from glutamine, can either directly contribute to the synthesis of 
GSH as a precursor, or play a role as a driver to exchange for cysteine through xCT. To 
understand how ASCT2 upregulates GSH level, we need to determine whether ASCT2 
increases GSH biosynthesis simply by directly increasing glutamine uptake and then 
converting glutamine to glutamate or also requires cooperation of the Xc(-) 
cystine/glutamate antiporter system. If xCT is also important in regulating GSH 
synthesis in ASCT2-inhibited cases, an xCT inhibitor, such as sulfasalazine, might be 
used to further increase the apoptotic effect induced by the combination of cetuximab 
and PDK1 targeting.  
        In conclusion, we demonstrated that combination of cetuximab and PDK1 targeting 
significantly induces apoptosis in vitro and in vivo, and the cytotoxic effect is 
independent of EGFR kinase activity inhibition induced by cetuximab. We discovered a 
novel role of cetuximab in regulating cellular redox status, by mediating internalization 
and degradation of EGFR-ASCT2 complex. Our findings will lead to a major advance in 
cetuximab-mediated EGFR targeted therapy by overcoming cetuximab resistance.  
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Chapter 6 Future direction 
 
6.1 Role of cetuximab-induced downregulation of HIF-1α in sensitizing HNSCC to 
radiation in vivo 
        Our data in Chapter 3 showed that cetuximab sensitized HNSCC cells to radiation 
measured by clonogenic assay. Overexpression of HIF-1α-∆ODD conferred resistance to 
cetuximab-induced anti-tumor effects, and also abolished the role of cetuximab in 
radiosensitization. This study could be expanded in vivo to determine the extent to which 
overexpression of HIF-1α will confer resistance to cetuximab and radiation, alone and in 
combination, in mice. HNSCC cells with and without overexpressing the HIF-1α-∆ODD 
construct will be implanted into SCID mice as xenografts. Mice bearing the xenografts 
will be treated with cetuximab or equal volume of PBS, either alone or in combination 
with radiation.  
        Another finding need to be confirmed in vivo is the extent to which targeting HIF-
1α through RNAi restores sensitivity of cetuximab-resistant HNSCC to cetuximab and 
radiation combination treatment. Although EGFR is highly expressed in most head and 
neck cancers, only a portion of EGFR-positive head and neck cancer respond to 
cetuximab treatment. Common resistant mechanisms include constitutive activation of 
important signaling molecules downstream of EGFR, such as oncogenic activation of 
Ras, or mutational inactivation of tumor suppressor, such as PTEN, or cross activation of 
EGFR downstream signaling pathways by other growth factor receptors, such as IGF-1R, 
or c-MET through tumor-stromal interactions, all of which may lead to partial or 
complete resistance to cetuximab treatment. To test our hypothesis in vivo, we will 
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establish a doxycycline-inducible HIF-1α-knockdown system and choose cetuximab-
resistant HNSCC cells that are experimentally established (HN5-RasG12V and FaDu-
RasG12V) and naturally occurring (OSC19 and UMSCC1) as our cell models. The cells 
expressing the inducible HIF-1α shRNA construct or control vector will be implanted 
into SCID mice as xenografts. Mice bearing xenograft will be fed with doxycycline-
containing water before radiation, with or without concurrent treatment with cetuximab. 
Mice without receiving any treatment will be included as the control groups.  
        Whether radiation itself can upregulate HIF-1α in human head and neck cancer 
cells in vivo, and whether it can be blocked by cetuximab treatment also need to be 
determined. HN5 and FaDu cells stably expressing the HRE-luciferase reporter construct 
or control vector will be implanted into SCID mice and irradiated at different doses, with 
or without one single dose of cetuximab right after radiation. Intratumoral HIF-1α 
activity will be monitored by real time in vivo imaging of luciferase activity in tumor 
xenografts at different time intervals after intraperitoneal injection of luciferin. The 
xenografts in some mice will be surgically removed after irradiation and subjected to 
immunohistochemical staining with an anti-HIF-1α antibody.   
 
6.2 Value of 18FDG-PET for early prediction of response to cetuximab 
        
18FDG-PET is commonly used in the clinic to detect cancers because of the 
enhanced uptake of glucose by cancer cells as a result of increased glycolysis and 
glucose transport. Our data showed that HIF-1α is downregulated by cetuximab in 
sensitive but not resistant cells and that downregulation of HIF-1α is required for 
cetuximab’s antiproliferative effects. HIF-1 plays a critical role in cancer cell growth and 
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survival by activating genes encoding for glycolysis. Thus, inhibition of glycolysis 
through targeting HIF-1α is an important mechanism underlying cetuximab’s 
antiproliferative effects. This novel concept of the mechanism of cetuximab could be 
used as a biomarker for early predication of responses to cetuximab treatment. We 
expect that cetuximab-sensitive cells will show reduced 18FDG uptake due to functional 
inhibition of glycolysis by cetuximab before tumor volumetric changes become apparent, 
whereas cetuximab-resistant cells will not show reduced 18FDG uptake.  
 
6.3 Role of AMPK-mediated energy homeostasis in mediating cancer cell resistance 
to cetuximab 
        Our findings in Chapter 4 established the impact of inhibition of bioenergetics and 
biosynthetic metabolism on cetuximab’s antiproliferative effects in cetuximab-sensitive 
HNSCC cell lines. However, the resistant mechanism to cetuximab, in the perspective of 
metabolism, is not clear. Unpublished data in our lab suggested that the activity of 
AMPK may protect cells from cetuximab treatment: specifically, co-treatment of 
cetuximab-resistant HNSCC cells with compound C, a small molecule AMPK inhibitor, 
induced apoptosis, whereas either agent alone had no such effect. AMPK is typically 
activated in response to reduced cell bioenergetics metabolism in order to maintain 
energy homeostasis by stimulating fatty acid oxidation [139, 140] and glycolysis [141, 
142], and suppressing cell biosynthesis through inhibition of the mTOR pathway and 
lipogenic pathways [143, 144]. AMPK can also be activated by Src activity through 
LKB1 independently of the AMP/ATP ratio in the cells [145-148]. Our lab previously 
reported that unsuppressed Src activity after cetuximab treatment is associated with 
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resistance to cetuximab [149]. We thus propose that unsuppressed Src activity confers 
resistance to cetuximab in part through regulating AMPK activity.  
        To confirm the role of AMPK in cancer cell response to cetuximab, we will 
compare the response to cetuximab of HNSCC cells with and without knockdown of 
AMPK expression by siRNA. If silencing AMPK enhances HNSCC cell response to 
cetuximab in vitro, we will expand the study to determine whether silencing of AMPK 
enhances response to cetuximab in vivo. We will establish a doxycycline-inducible 
AMPK-knockdown system and transfect the constructs containing doxycycline-
inducible AMPK shRNA or control shRNA into luciferase positive, cetuximab resistant 
HNSCC cell lines and select stable expression pooled cells. Successfully characterized 
cells will be implanted as xenografts. Mice with established xenograft will be treated 
with cetuximab or equal amount of PBS with or without concurrent exposure to 
doxycycline added into the drinking water.  
 
6.4 Role of ASCT2 in resistance to apoptosis induced by overproduction of ROS 
        In 5.2.7 and 5.2.8, we showed that DCA and other ROS inducer, including H2O2, 
pyocyanin, and PEITC, upregulate ASCT2. However, the underlying mechanism is 
unknown. To elucidate the mechanisms by which ROS leads to upregulation of ASCT2, 
we will perform ASCT2 real-time PCR, luciferase reporter assays and 35S-metabolic 
pulse chase assays. Depending on whether these assays reveal a transcriptional or a 
posttranslational mechanism or both, we will pursue additional studies to identify 
molecular players and the mechanisms through which ROS upregulate ASCT2.  
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        As discussed in 5.3, how glutamine, which is uptaken by ASCT2, contributes to 
GSH synthesis is not clear. Glutamine is converted to glutamate within the cells 
catalyzed by glutaminase. Glutamate can either directly contribute to GSH synthesis one 
of the precursors, or work as the driving force for the uptake of cystine, which is 
considered to be the rate-limit precursor for the synthesis of GSH, through Xc(-) 
cystine/glutamate antiporter system. We will address this question by assessing whether 
knockdown of xCT has any effect on ASCT2-stimulated GSH synthesis. To further 
determine whether ASCT2 is an independent determinant of GSH biosynthesis, we will 
add reducing agent β-mercaptoethanol into cell culture medium, which will chemically 
reduce cystine to cysteine and thus provide an unrestricted source of cysteine for GSH 
synthesis independent of xCT, and examine whether knockdown of ASCT2 affects GSH 
biosynthesis.   
        The role of ASCT2 in protecting cells from ROS-induced apoptosis could be 
confirmed in vivo. We will establish a doxycycline-inducible ASCT2-knockdown 
system. The HNSCC cells expressing the inducible ASCT2 shRNA construct or control 
vector will be implanted into nude mice as xenografts. Mice bearing xenograft will be 
fed with or without doxycycline-containing water, and with or without treatment of DCA.  
 
6.5 Mechanism of interaction between EGFR and ASCT2  
        In 5.2.10, we showed that ASCT2 is associated with EGFR. Next, we will 
investigate how EGFR and ASCT2 form a complex. We will co-transfect HEK293 cells 
with ASCT2 and one of each of the following EGFR constructs: wild-type EGFR, 
kinase-dead EGFR, extracellular-domain EGFR, intracellular-domain EGFR, and the 
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juxtamembrane region plus the kinase domain. We will determine which part on the 
EGFR molecule is required for pull-down with ASCT2 by co-immunoprecipitation using 
ASCT2 antibody.  
 
6.6 Effect of inhibiting xCT on improving the therapeutic outcome of combination 
treatment with cetuximab plus DCA in vitro and in vivo  
        In Figure 33A, we found that there was a compensatory increase in the level of xCT 
after downregulation of ASCT2 be cetuximab, which may increase intracellular GSH 
level via increasing cysteine uptake and lead to resistance to the combination treatment 
of cetuximab and PDK1 targeting. We hypothesize that adding xCT inhibitor 
sulfasalazine to combination treatment with cetuximab plus DCA improves the 
therapeutic outcome. We will confirm the inhibitory effect of sulfasalazine on the Xc(-) 
system by measuring the level of 35S-cystine uptake with or without sulfasalazine 
treatment in HNSCC cells. We will examine whether the compensatory increase in xCT 
induced by cetuximab is accompanied by increased 35S-cystine uptake. We will then 
determine whether addition of sulfasalazine increases the induction of ROS and 
apoptosis by the combination of cetuximab and DCA in cultured HNSCC cells. To 
determine whether sulfasalazine can significantly improve the therapeutic outcome in 
vivo, we will compare the responses of HNSCC xenografts to the combination of 
cetuximab and DCA, with and without sulfasalazine, as well as any treatment alone.  
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